Review Article | Open Access
Amin Majdalawieh, Hyo-Sung Ro, "Regulation of IB Function and NF-B Signaling: AEBP1 Is a Novel Proinflammatory Mediator in Macrophages", Mediators of Inflammation, vol. 2010, Article ID 823821, 27 pages, 2010. https://doi.org/10.1155/2010/823821
Regulation of IB Function and NF-B Signaling: AEBP1 Is a Novel Proinflammatory Mediator in Macrophages
NF-B comprises a family of transcription factors that are critically involved in various inflammatory processes. In this paper, the role of NF-B in inflammation and atherosclerosis and the regulation of the NF-B signaling pathway are summarized. The structure, function, and regulation of the NF-B inhibitors, IB and I, are reviewed. The regulation of NF-B activity by glucocorticoid receptor (GR) signaling and IB sumoylation is also discussed. This paper focuses on the recently reported regulatory function that adipocyte enhancer-binding protein 1 (AEBP1) exerts on NF-B transcriptional activity in macrophages, in which AEBP1 manifests itself as a potent modulator of NF-B via physical interaction with IB and a critical mediator of inflammation. Finally, we summarize the regulatory roles that recently identified IB-interacting proteins play in NF-B signaling. Based on its proinflammatory roles in macrophages, AEBP1 is anticipated to serve as a therapeutic target towards the treatment of various inflammatory conditions and disorders.
1. NF-B Signaling Pathway
The ability to sense external stimuli that could be lethal to cells coupled with the potential to respond to such cytotoxic signals by switching on defensive genes to sustain cell growth and survival is a remarkable facet of nuclear factor kappa B (NF-B). Since NF-B is ubiquitously expressed in almost all types of cells and is a transcription factor that is sequestered in an inactive state in the cytosol but can become activated by a wide range of diverse internal and external stimuli, NF-B has long been considered an ideal safeguard to defend the cell against countless stimuli and maintain its homeostasis . Moreover, NF-B is a unique transcription factor in that its function is not solely dependent on its expression when needed. Rather, NF-B is constitutively expressed in the cell, but it does not become active until it is called upon for action, in which it will be ready and its mission can be accomplished in a timely regulated fashion.
NF-B comprises a family of ubiquitously expressed, eukaryotic transcription factors that participate in the regulation of multiple immediate genes that are expressed at the onset of many vital biological processes such as cell growth, immunoregulation, apoptosis, and inflammation [2, 3]. Modulation of NF-B activity can lead to many abnormal cellular processes and diseases including asthma, arthritis, atherosclerosis, obesity, and various types of cancers [2–7]. NF-B exists in cells as a heterodimer of members of the Rel family of proteins, including p50, p52, p65 (RelA), RelB, and c-Rel, which share a high degree of structural similarity (Figure 1).
2. Roles of NF-B in Inflammation and Atherosclerosis
One of the major functions of NF-B is its key involvement in inducing an effective immune/inflammatory response against viral and bacterial infections. The importance of NF-B role in initiating a potent inflammatory response cannot be better signified than recognizing that the B consensus sequence is found in the promoter/enhancer regions of more than 50 diverse genes whose expression is known to be crucial in driving an inflammatory response [8–10]. Inducible genes that are known to be transactivated by NF-B include, but are not limited to, IL-1, IL-6, IL-8, TNF, IFN, MCP-1, iNOS, COX-2, intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) [2, 3, 10–19]. These molecules play critical roles in key biological events involving cell recruitment, attachment, differentiation, proliferation, and activation constituting an active inflammatory response. NF-B is also known to cooperate with other active transcription factors such as activator protein-1 (AP-1) in upregulating the expression of some MMPs [20, 21], which play destructive roles in atherosclerotic lesions rendering them unstable and prone to rupture.
Genetic knockout models have provided lucid evidence that NF-B proteins are absolutely essential for the development of a normal, effective immune system, since NF-B genetic ablation, in general, renders mice immunocompromised and prone to pathogenic infections. Specifically, mice develop normally but are defective in immunoglobulin production, and thus, humoral immune responses . Likewise, mice develop normally but their B-cell follicles and germinal centers do not develop normally, and the mice are unable to launch an adequate humoral response against T-cell-dependent antigens [23, 24]. Although ablation of p65 causes embryonic lethality due to liver apoptosis , ablation of TNF or TNFR rescues from the lethal phenotype [26, 27]. However, / mice are highly susceptible to bacterial infections and unable to provoke an innate immune response. In addition, T and B lymphocytes of c- mice are unresponsive to various mitogenic stimuli, and the mice are unable to generate a humoral immune response . Lastly, mice are severely defective in generating adaptive immune responses . Thus, it is evident that NF-B proteins are indispensable in generating effective inflammatory, innate, and adaptive immune responses against viral and bacterial pathogens.
The first experimental evidence of NF-B role in atherosclerosis, a progressive inflammatory disease, came from a study demonstrating that active NF-B can be detected in aortae with evident atherosclerotic lesions but not in normal, nonlesional aortae . In fact, a strong signal of active NF-B can be detected in endothelial cells, macrophages, and to a lesser extent, T lymphocytes within atherosclerotic lesions [30, 31]. Interestingly, oxLDL is potentially capable of activating NF-B in endothelial cells and macrophages in culture systems as well as in atherosclerotic lesions [32–35]. In the context of atherosclerosis, NF-B activation is believed to promote the expression of various factors that mediate various processes such as proliferation, chemotaxis, adhesion, inflammation, and thrombosis, key events in atherogenesis . Wolfrum and colleagues have shown that mice which overexpress TNF-inducible protein A20, a cytosolic zinc finger protein that inhibits NF-B activity by blocking IB degradation, display significantly smaller atherosclerotic lesions compared to control mice . A recent study has clearly demonstrated that endothelium-specific inhibition of NF-B activity is accompanied by significant reduction in atherosclerotic lesion formation in apolipoprotein E null () mice . In fact, inhibition of NF-B leads to abrogated macrophage recruitment to the atherosclerotic lesions and reduced expression of cytokines and chemokines in the aortae of mice . Indeed, a large number of naturally occurring products have been shown to attenuate the pathogenesis of atherosclerosis by virtue of their ability to interfere with NF-B signaling [39–43]. Furthermore, several studies have demonstrated a positive correlation between NF-B activity and incidence of myocardial infarction [44–51]. Due to its critical role in atherosclerosis and myocardial infarction, NF-B is proposed to be a promising therapeutic target for reducing, if not eliminating, the risks of atherosclerosis and its complications.
3. Structure of NF-B/Rel Proteins
Although several homodimers and heterodimers are formed by various members of the NF-B protein family, NF-B is a term that is often used to describe the p50/p65 heterodimer, which was the first NF-B dimer to be described [18, 52]. Indeed, p50 and p65 are the first members of the NF-B gene family to be cloned and characterized [53–56]. As shown in Figure 1, members of the NF-B/Rel protein family contain a highly conserved, N-terminal 300-amino acid region known as the rel homology domain (RHD), which mediates dimerization, interaction with IB proteins, nuclear translocation due to the presence of a nuclear localization signal (NLS) within RHD, as well as binding to specific sites within the promoters of target genes . Although the majority of NF-B dimers are capable of transactivating target genes, in vivo data demonstrated that some dimers such as p50/p50 and p52/p52 homodimers can be inactive or repressive [57–59]. The fact that p50 and p52 lack a C-terminal region that is conserved in the majority of other NF-B proteins suggests that this region confers on NF-B proteins a transcriptional potential, and hence, it is called the transactivation domain (TAD) . Mutations of important residues within TAD render activating NF-B dimers transcriptionally inactive . RelB is a structurally unique member of the NF-B protein family in that it contains a leucine zipper-like (LZ) region at its N-terminus, which is required for its full transcriptional activity .
4. Regulation and Activity of NF-B/Rel Proteins
Under basal conditions, most NF-B subunits are sequestered in the cytosol, where they are constitutively bound by members of the NF-B inhibitor family of proteins, mainly IB and IB [54, 62]. However, diverse stimuli including inflammatory cytokines, mitogens, lipopolysaccharides, UV light, as well as bacterial and viral pathogens can transduce a signal that ultimately results in NF-B liberation from its inhibitors, allowing NF-B dimers to translocate to the nucleus and become transcriptionally active [9, 63, 64]. Except for RelB, all other NF-B proteins contain a protein kinase A (PKA) phosphorylation site 20–30 amino acids N-terminal of the NLS within RHD, and phosphorylation of this site (S337 in p50 and S276 in p65) seems to be essential for nuclear translocation [65, 66]. Moreover, phosphorylation of the PKA phosphorylation site is important in protecting the transcriptional and DNA-binding activities of active NF-B dimers [67–70]. Studies have shown that S276 in p65 is a major phosphorylation site that is subject to compartment-specific and stimulus-specific phosphorylation by PKAc in the cytoplasm  and the mitogen- and stress-activated protein kinase-1 (MSK1) in the nucleus . S276 phosphorylation is required for optimal NF-B activity in different cell types [71–73]. Other important phosphorylation sites have been demonstrated to be critical for optimal NF-B transactivation potential. Such sites include protein kinase C zeta-(PKC-) phosphorylated S311 , casein kinase II (CKII)-phosphorylated S529 , IKK/-phosphorylated S536 [76–78]. S536 in p65 has also been shown to be subject to phosphorylation by other kinases such as AKT/protein kinase B (PKB) [79, 80], ribosomal S6 kinase 1 (RSK1) , TRAF family member-associated (TANK)-binding kinase 1 (TBK1) [82, 83], and IKK  under certain circumstances.
Dimerization of NF-B proteins is a prerequisite for NF-B to become transcriptionally active, and it is mediated by specific motifs within RHDs of both members of NF-B dimers . Studies have shown that the dimerization motifs are located at the C-terminus of RHD, and mutation of critical residues within such motifs interferes with dimerization [84–86]. Site-directed mutagenesis experiments also revealed the importance of certain residues within the dimerization motifs in determining partner specificity [85–87]. Once in the nucleus, active NF-B dimers can bind to specific DNA-binding sites, known as B binding sites, within the regulatory regions of their target genes, leading to gene transactivation [10, 88]. The B site has a conserved consensus sequence of 10 nucleotides (GGGRNNYYCC where N is any base, R is a purine, and Y is a pyrimidine), and slight variations of the B nucleotide sequence confer preference to different dimer combinations of NF-B subunits [9, 88]. The N-terminus of RHD is known to be essential for DNA-binding activity of NF-B proteins [84, 89]. Although point mutations of specific residues within this region do not interfere with dimerization, they completely abrogate the DNA-binding activity of NF-B dimers [84, 90].
5. Inhibitors of NF-B
Work from Baltimore’s laboratory provided initial characterization of NF-B coordinate regulation via physical interaction with its inhibitors, members of the IB family of proteins [8, 91]. The observation that nuclear NF-B exists in an IB-unbound state indicated that IB proteins can sequester NF-B in an inactive state in the cytosol. Initial characterization of IB proteins that associate with NF-B led to the identification of 37-kDa and 43-kDa proteins, which are now known as IB and IB, respectively . IB and IB are the most well-characterized members of the mammalian IB family of proteins, which contains a number of structurally related proteins besides IB and IB, including IB1, IB2, IB, IB, IBR, IBL, p100, p105, and Bcl-3 [9, 93]. Recently, a new member of the IB protein family was identified and named IB . Except for Bcl-3 and IB, which are constitutively localized in the nucleus [94, 95], all other IB proteins are localized in the cytosol . Nuclear localization of Bcl-3 and IB indicates that these proteins do not regulate NF-B translocation into the nucleus, but rather, they seem to be involved in regulating NF-B transcriptional and DNA-binding activities [94, 96–98].
6. Structure of IB and IB
Structural organization of IB proteins started to be uncovered upon molecular cloning and characterization of the IB gene (also known as MAD-3) in the early 1990s [99, 100]. Now, it is clear that all IB proteins known to date possess three to seven centrally located, 30–33 amino acid repeated sequences known as ankyrin (ANK) repeats (also known as notch-related motifs, cell cycle repeats, and cdc10/SW16 repeats) (Figure 1) [9, 93, 101]. These repeats were initially identified in the SW16 protein expressed by Saccharomyces cerevisiae . Although the exact amino acid sequences of ANK repeats found in different IB proteins can be distinct, ANK repeats have a consensus amino acid sequence (XGXTPLHLAARXGHVEVVKLLLDXGADVNAXTK, where X can be any amino acid) [103, 104]. Even within the same IB protein, ANK repeats can be quite distinct, and this is thought to be an important determinant in the specificity and selectivity of the protein-protein interaction between IB and NF-B proteins . The presence of ANK repeats in IB proteins renders them capable of physically interacting with regions within the RHD of target NF-B dimers [106–108]. Additionally, IB, IB, and IB have N-terminal signal-receiving domain (SRD) containing two highly conserved serine residues, which are known to be important phosphorylation sites involved in the regulation of IB function [9, 93]. IB, IB, IB1, IB2, IB, IBR, IBL, p100, and p105 contain a region at the C-terminus that is rich in proline, glutamate, aspartate, serine, and threonine residues, and hence, it is called the PEST domain [9, 93]. The PEST domain plays an important role in the inhibition of NF-B DNA-binding activity , as well as in IB protein stability/turnover [52, 110–113]. Although deletion of the N-terminus and/or the C-terminus does not affect IB ability to interact with NF-B dimers, point mutations of certain residues within the N-terminus of IB render it resistant to signal-induced phosphorylation and degradation [114–117], while deletion of the C-terminus of IB interferes with its ability to dissociate NF-B from its DNA binding sites [107, 109, 118]. Finally, two nuclear export signal (NES) sequences have been identified in the N-terminus  and C-terminus of IB . Actually, the more conserved N-terminal NES was shown to be necessary and sufficient for IB nuclear export . Efficient nuclear translocation and cytosolic relocalization (i.e., nuclear export) of IB is ensured by the presence of NLS and NES, respectively.
7. Function of IB and IB
Since IB and IB are the best studied members of the IB protein family, special emphasis will be allotted to these two molecules throughout this paper. Members of the IB protein family are constitutively and ubiquitously expressed proteins that localize in the cytosol, except for Bcl-3 and IB which are primarily present in the nucleus [94, 95]. The main function of IB proteins is to inhibit NF-B activity when it is not required, and this happens via protein-protein interaction that takes place between IB proteins and NF-B dimers in the cytosol. IB and IB interact via their ANK repeats with the RHD of NF-B dimerized proteins in such a way that masks the positively charged regions of the NLSs within the RHDs of NF-B dimers [121, 122]. As a result, NF-B dimers are prevented from translocating to the nucleus, and thus, they are kept in an inactive, IB-bound state in the cytosol [123–125]. Although IB-NF-B interaction is mediated by ANK repeats of IB proteins, not all ANK repeats are involved in this interaction [107, 118, 126]. In an extensive site-directed mutagenesis study performed to assess the significance of every ANK repeat within IB , a number of interesting findings were revealed. First, the C-terminus of IB is required for the protein to be functional, and thus, the ANK repeats are not sufficient on their own to exert an inhibitory action towards NF-B. Second, lack of the third ANK repeat does not impede IB inhibitory function, suggesting that this ANK repeat is dispensable for IB inhibitory function. Third, the only mutant forms of IB that are unable to inhibit NF-B activity are those that were incapable of interacting with NF-B. Another study suggests that the first ANK repeat of IB is mostly responsible for its inhibitory activity, and substituting the first ANK repeat in IB with that of IB significantly enhances the former’s inhibitory activity . It is evident that the ANK repeats and the C-terminal region (i.e., PEST domain) of IB form a tertiary structure that is capable of interacting with NF-B proteins, and that such interaction confers NF-B transcriptional inactivity .
It is known that NF-B is itself an upregulator of IB and IB, in which NF-B activation via various and distinct stimuli is usually followed by rapid induction of IB and IB expression [19, 52, 128] due to the presence of a B DNA-binding site within the IB promoter [129–131]. This negative feedback regulatory loop sets a molecular switch that ensures rapid, controlled, and transient activation of target genes by NF-B. Induced expression of IB allows translocation of nascently synthesized IB into the nucleus, where it binds to active NF-B dimers that are bound to B sites within the promoters of their target genes. Interaction between nuclear IB and active NF-B dimers leads to dissociation between NF-B dimers and DNA, and it forces a conformational change in IB that exposes the nuclear export signal (NES), eventually leading to resequesterization of IB and NF-B dimers in the cytosol [92, 120, 132]. This highly complex, tightly regulated reciprocal regulatory process involving NF-B and IB proteins confers the NF-B signaling pathway a central regulatory function in many key biological events that requires transient, short-term NF-B activity.
8. Regulation of IB and IB
There are at least two well-characterized signaling pathways leading to NF-B activation, classical and alternative, and both rely on the catalytic activity of known IB kinases (IKKs) (Figure 2). The classical NF-B signaling pathway is typically triggered by a vast number of proinflammatory cytokines (e.g., IL-1 and TNF), viruses, and bacteria, and hence, it leads to a coordinate inflammatory/immune response culminating in the expression of multiple cytokines, chemokines, adhesion molecules, and proinflammatory proteolytic enzymes [133, 134]. On the other hand, the alternative NF-B signaling pathway is normally triggered by non-proinflammatory cytokines (e.g., lymphotoxin (LT), B-cell activating factor (BAFF), and CD40 ligand (CD40L)) as well as some viruses (e.g., human T-cell leukemia virus (HTLV) and Epstein-Barr virus (EBV)) [133, 134]. The alternative NF-B signaling pathway is triggered to induce the expression of genes whose products play fundamental roles in the development and maintenance of secondary lymphoid organs . Unlike the classical pathway, the alternative pathway is NEMO independent in that it does not require the IB kinase (IKK) complex, which contains the scaffold protein NF-B essential modulator (NEMO), IKK, IKK, IKK, and other adaptor proteins [133–140]. Instead, the alternative pathway relies on the activity of the NF-B inducing kinase (NIK) that transactivates IKK-IKK homodimers, which upon activation transduce a signal that culminates in profound NF-B activation . In the next sections, special attention will be paid to the classical NF-B signaling pathway.
9. Basal Turnover/Degradation of IB and IB
Besides signal-induced proteolytic degradation of IB and IB, these proteins have been shown to be susceptible to degradation under basal, unstimulatory conditions. In fact, IB and IB have been shown to be constitutively phosphorylated in absence of stimuli [67, 141], and specific serine/threonine residues (S283, S289, S293, and T291) within the PEST domain of IB have been shown to be the target of constitutive phosphorylation by CKII [111, 113, 117, 142]. Phosphorylation of the PEST domain renders IB susceptible to degradation, indicating that the PEST domain is essential for controlling IB intrinsic protein stability [111–113]. Likewise, it was shown that the PEST domain of IB is required for its degradation . Unlike signal-induced degradation of IB, which required ubiquitination, basal degradation of IB seems to be ubiquitination independent, in which degradation of unubiquitinated IB is evident in unstimulated cells in vitro . This data is supported by the observation that a mutant form of IB carrying lysine-to-arginine substitutions at the two ubiquitination sites (K21 and K22) is as prone to basal degradation as the wild type form (WT) of IB . In other words, ubiquitination of IB is a signal-induced event and is not required for basal degradation of IB. However, the ubiquitin-independent IB degradation pathway is proteasome dependent, since proteasome inhibitors block basal, as well as signal-induced, degradation of IB .
Until the emergence of a paper published by Phillips and Ghosh in 1997 , the 26S proteasome-mediated proteolysis pathway was the only known cellular process responsible for basal and signal-induced degradation of IB and IB. However, the use of selective proteasome inhibitors revealed the existence of a novel proteolysis pathway that leads to IB and IB degradation in an ubiquitin-independent, proteasome-independent manner in immature B cells [146, 147]. Indeed, such a novel pathway was subsequently shown to be dependent on the presence of free calcium, most likely imported from outside the cell . Further examination of this pathway revealed that phosphorylation of the PEST domain of IB allows it to bind to the calmodulin-like domain (CaMLD) of the large subunit of the calcium-dependent thiol protease complex, calpain [148, 149]. Interaction between IB and calpain is followed by N-terminal cleavage and further proteolysis of IB [148, 149]. These studies suggest that IB and IB can also be regulated by protease machineries other than the intrinsic, well-known 26S proteasome complex.
10. Signal-Induced IB and IBPhosphorylation by the IKK Complex
In order for NF-B to become activated, IB/ must become phosphorylated at specific serine residues at the N-terminus, followed by ubiquitination (not for IB) and proteolytic degradation of phosphorylated IB and IB in the cytosol. Phosphorylation and subsequent proteolytic degradation of IB and IB liberate NF-B dimers, which become phosphorylated, translocate to the nucleus, and bind to specific B binding sites within the promoter/enhancer regions of their target genes, leading to their transactivation. Binding of TNF to its receptor (TNFR1) is known to trigger NF-B activation through the classical pathway, leading to TNF-induced cell death . Under basal conditions, constitutive activation of the TNF-induced cell death pathway is prevented by the blocking potential of a protein called the silencer of death domains (SODDs), which binds to TNFR1 and prevents downstream signal transduction . Upon TNF-TNFR1 binding, SODD dissociates from TNFR1 and this allows recruitment of adaptor molecules TNF receptor-associated death domain (TRADD), receptor interacting protein (RIP), and TNFR associated factor 2 (TRAF2), which bind to TNFR1 as a complex through TRADD. Sequential recruitment of NIK and the IKK complex to the TRADD complex bound to TNFR1 is mediated by TRAF2 [151, 152]. Stimulation signals triggered by LPS, IL-1, and TNF also lead to the recruitment and activation of MEKK1 . The recruited IKK complex also contains an IB kinase regulatory subunit called ELKS (glutamic acid, leucine, lysine, and serine-rich protein), which allows IB recruitment and interaction with the IKK complex at the membrane . Although NEMO, IKK, IKK, IKK, and ELKS are the main components of the cytoplasmic serine-protein-kinase multi-subunit IKK complex, other proteins are identified as essential elements of the complex [135–140, 155–157]. NIK and MEKK1 are upstream upregulators of the IKK complex, in which they phosphorylate and transactivate IKK and IKK within the complex [155, 158].
Membrane recruited IKK complex with catalytically active IKK and IKK is responsible for phosphorylating two N-terminally located conserved serine residues in IB and IB (Ser32 and Ser36 in IB; Ser19 and Ser23 in IB) [137, 159]. Interestingly, cell lines that lack NEMO display severe defects in NF-B activation and they are unresponsive to a wide range of potent stimuli , indicating that catalytically active IKK and IKK are insufficient in phosphorylating IB and IB in the absence of complex formation. Although some studies have initially suggested a major role of IKK in IB and IB phosphorylation [135, 137, 156, 160, 161], a study demonstrated that mutation of two serine residues within the activation loop of IKK, but not IKK, renders the IKK complex catalytically inactive , indicating that IKK is the predominant kinase component of the IKK complex. This observation is supported by an experiment demonstrating that cells display normal IKK activity towards IB and IB upon LPS, IL-1, and TNF treatment . Moreover, mice resemble mice in that they suffer from embryonic lethality due to severe liver apoptosis . The apoptotic phenotype of mice combined with the observation that TNF deficiency eliminate embryonic lethality of mice  and that NF-B mediates TNF-induced apoptosis  strongly suggest that IKK catalytic activity is absolutely required for NF-B activation. Direct experimental evidence indicates that embryonic stem cells and fibroblasts display defective IKK activity towards IB, and no NF-B activity . These findings indicate that IKK cannot compensate for IKK loss, and that IKK is solely responsible for phosphorylating IB and IB in vivo. Interestingly, phosphorylation of S32/S36 and S19/S23 in IB and IB, respectively, does not force IB and IB dissociation from their NF-B dimer partners in the cytosol [116, 167], but it renders them susceptible to ubiquitination and subsequent proteolytic degradation [101, 167–171].
11. Signal-Induced Degradation of IB and IB
Proteolysis, or proteolytic degradation, is a highly regulated cellular multistep process that involves enzymes called proteases that are capable of hydrolyzing peptide bonds within polypeptides that are usually ubiquitinated, ultimately leading to protein degradation (Figure 3). Protein ubiquitination and subsequent degradation were thought to be molecular mechanisms undertaken by cells to eradicate misfolded or defective proteins [172, 173]. Nevertheless, it is well recognized that protein degradation is a process that is not directed only against imperfect proteins, but also against some fully functional proteins as a means to regulate and control various key biological processes . Cyclins, proteins involved in the regulation of the cell cycle, are a prime example of functional proteins that are regulated by ubiquitination-dependent proteolytic degradation pathways [174, 175].
It is evident that signal-induced phosphorylation of IB and IB must be followed by their degradation for NF-B transactivation potential to be manifested [167, 176–182]. The most compelling evidence indicating the necessity of IB and IB degradation for NF-B activation came from a study showing that treatment of stimulated cells with protease inhibitors does not eliminate phosphorylation of IB and IB, but protects NF-B-IB and NF-B-IB cytosolic complexes, and thus, prevents NF-B activation [143, 167, 178, 181, 182]. Under stimulatory conditions, proteolytic degradation of IB and IB occurs via an ubiquitination- and proteasome-dependent mechanism [169, 170].
The 26S proteasome is composed of a core protease, known as the 20S proteasome, and the 19S regulatory complex (RC), which is composed of at least 18 different subunits in two subcomplexes known as the lid and the base . The involvement of the 26S proteasome in signal-induced NF-B activation was originally signified by studies demonstrating that treatment with selective inhibitors of the 26S proteasome blocks NF-B activation [178, 184]. Subsequent to phosphorylation of the two serine residues within the signal-induced kinase domain of IB, multiple 76-amino acid ubiquitin polypeptides covalently attach to the N-terminus of phosphorylated IB, rendering IB proteins susceptible to 26S proteasome-dependent degradation [169, 170, 185, 186]. For IB, ubiquitination primarily takes place on two adjacent lysine residues (K21 and K22) in the N-terminus of the protein, and mutation of these two lysine residues prevents IB ubiquitination and subsequent proteolytic degradation [187, 188]. Indeed, conservative substitution of K21 and/or K22 by arginine precludes not only ubiquitination, but also signal-induced degradation of IB, ultimately preventing NF-B activation [187, 188]. During initial characterization of IB regulation, it was shown that treatment of cells with protease inhibitors prevents IB degradation , suggesting that IB may be under control of the ubiquitin-proteasome machinery in a phosphorylation-dependent fashion, as in IB. Indeed, site-directed mutagenesis of S19 and/or S23 renders IB somewhat resistant to degradation . Strikingly, however, alanine substitution of K9 has no effect on IB degradation , indicating that ubiquitination is not a prerequisite for IB degradation. So, although phosphorylation of the two, N-terminal conserved serine residues is required for inducing IB and IB degradation, ubiquitination of the N-terminal lysine residues is required for proteasome-dependent degradation of IB, but not IB. Interestingly, although the PEST domain of IB and IB is not required for S32/S36 and S19/S23 phosphorylation, respectively, its deletion eliminates signal-induced degradation of IB [115, 117, 189–191] and IB [192–194]. In sum, for signal-induced NF-B transactivation activity to manifest, at least six main biochemical events must precede: (1) phosphorylation of IB and IB by the IKK complex, (2) ubiquitination of phosphorylated IB, (3) proteasome-mediated degradation of IB and IB, (4) phosphorylation of NF-B dimer, (5) nuclear translocation of NF-B dimer, and (6) NF-B dimer-B DNA interaction (Figure 3).
12. Regulation of NF-B Activity via IB Sumoylation
Signal-induced IB phosphorylation and ubiquitination, followed by its proteolytic degradation, are not the only posttranslational modifications that target IB and regulate NF-B activity in cells. Sumoylation is defined as process by which a small ubiquitin-like modifier (SUMO) (20 kDa) is covalently attached to lysine residues on target proteins [195–197]. Similar to ubiquitination, the process of sumoylation involves three enzymatic events that proceed sequentially, ultimately culminating in SUMO conjugation to the protein substrate by forming an isopeptide bond between SUMO and the -amino group of a lysine side chain . In 1998, Desterro and colleagues have reported for the first time the existence of a modified, slower migrating form of IB . This modified, slower migrating protein has been identified as an SUMO-1-modified IB in several mammalian cells including human embryonic kidney HEK 293 cells, monkey COS-7, human T leukemic Jurkat cells, and HeLa cells . Intriguingly, only a small fraction of total IB protein was found to be modified by SUMO-1, and the degree of sumoylation varied depending on the cell type with 50% being the maximum proportion of sumoylated IB of the total IB pool . Notably, nuclear localization of IB was deemed necessary for its sumoylation . Significantly, the sumoylated form of IB was further shown to be highly resistant to signal-induced ubiquitination and subsequent proteasome-mediated degradation compared to unmodified IB . Desterro and colleagues went on to show that overexpression of SUMO-1 inhibits signal-induced activation of NF-B-dependent transcription. In a later study, Guo and colleagues have reported the identification and cloning of SUMO-4, which was proposed to conjugate with IB leading to NF-B downregulation . Very recently, SUMO-4-mediated downregulation of NF-B was shown to be dependent on modification of IB by SUMO-4 . Intriguingly, a B binding motif was also identified in SUMO-4 promoter, and mutagenesis of this motif interfered with NF-B-dependant transactivation of its target genes, suggesting a feedback loop mechanism by which SUMO-4 regulates NF-B activity .
Unlike ubiquitination, which requires phosphorylation at S32 and S36, phosphorylation at these sites interferes with IB sumoylation , likely due to a conformational change that hinders SUMO-1 conjugation. Using site-directed mutagenesis, it was also shown that SUMO-1 conjugation requires K21 and K22 at the N-terminus of IB; with K21 being the primary site for sumoylation . Strikingly, K21 and K22 are the target residues for ubiquitination, providing a plausible explanation for the prolonged stability of sumoylated IB compared to unmodified IB. This observation also suggests that SUMO-1 and ubiquitin molecules compete for these residues to regulate IB function, and thus, NF-B activity. Moreover, many hydrolases that can potentially cleave the bond between SUMO-1 and its targeted lysine residue on the substrate, hence known as desumoylating enzymes, have been identified [203–206]. Hence, controlling the balance between sumoylation and desumoylation of IB may serve as a mechanism underlying the regulation of NF-B activity. Sumoylation of IB may be a physiologically significant anti-inflammatory mechanism undertaken by cells to suppress lethal inflammatory responses via converting IB proteins from their degradation-susceptible, unmodified form into a degradation-resistant, sumoylated one. Interestingly, in an in vitro study, it was demonstrated that epithelial cells exposed to increasing periods of hypoxia; a condition that triggers a wide range of inflammatory events, responded by increasing the proportion of SUMO-1-bound IB and cAMP-response element-binding protein (CREB) ; a transcription factor that induced the expression of various proinflammatory cytokines. Consistently, induced hypoxia led to a significant increase in transcriptional expression of SUMO-1 . Very recently, it was demonstrated that adenosine signaling mediates SUMO-1 modification of IB during hypoxia . Several studies have demonstrated a tight link between SUMO-4 polymorphism and susceptibility to type-I diabetes [201, 209, 210]. However, this correlation between SUMO-4 polymorphism and susceptibility to type-I diabetes seems to be more prevailing among Asian populations compared to Caucasians. Wang and colleagues have recently reviewed the correlation between SUMO-4 polymorphism and type-I diabetes, and they provided some insights to explain the discrepancy noted among different populations and the mechanisms through which SUMO4 contributes to the pathogenesis of type-I diabetes . SUMO-4 polymorphism seems to have no correlation with susceptibility of other inflammatory conditions including Grave’s disease , rheumatoid arthritis [213–215], and systemic lupus erythematosus . Finally, it is conceivable that modulation of IB sumoylation may be utilized as a mechanism to aggravate or alleviate the symptoms of various NF-B-driven inflammatory conditions.
It is important to mention that other proteins involved in NF-B signaling pathways are also subject to sumoylation. For example, sumoylation on K277 and K309 residues of NEMO by SUMO-1 conjugation has been shown to mediate NF-B activation by genotoxic stress . In fact, regulation of NF-B activity by NEMO sumoylation occurs under a variety of other stress conditions including oxidative stress, ethanol exposure, heat shock, and electric shock . Details regarding the mechanisms involved in NEMO sumoylation were revealed by a recent study demonstrating that NEMO sumoylation is mediated by protein inhibitor of activated STATy (PIASy), which seems to preferentially stimulate site-selective modification of NEMO by SUMO-1, but not SUMO-2 or SUMO-3, in vitro .
13. Cross-Talk between Glucocorticoid Receptor (GR) and NF-B Signaling
Although signal-induced posttranslational modification of IBs by phosphorylation, ubiquitination, sumoylation, and proteolytic degradation serves as the central molecular mechanism by which NF-B signaling is regulated, several IB-independent mechanisms have been proposed as effective, alternative cellular events that are crucial in the regulation of NF-B activity. Such IB-independent mechanisms seem to be critical in the alternative, noncanonical NF-B signaling pathway and they occur via post-translational modification of various proteins, other than IBs, that are critically involved in NF-B signaling. Like IBs, some members of the Rel family of proteins can be subject to signal-induced post-translational modifications that ultimately lead to modulation of NF-B activity [134, 220, 221]. Signal-induced phosphorylation of RelA, which was first documented about fifteen years ago [67, 141], is by far the most extensively studied post-translational modification in the regulation of NF-B signaling (for review, refer to [134, 220, 221]). Similarly, post-translational modifications of RelB [222, 223], c-Rel [224–229], and p50 [67, 230] have also been documented as IB-independent regulatory mechanisms involved in NF-B signaling.
Moreover, other IB-independent mechanisms involving a complex interplay between NF-B and other NF-B-unrelated proteins have been recently revealed. The glucocorticoid receptor (GR) is a prime example of such regulatory proteins that are critically implicated in the control of NF-B signaling pathways. GR is a hormone-dependent transcription factor belonging to the nuclear receptor superfamily, and it is critically involved in mediating the immunosuppressive functions of glucocorticoids by repressing the expression of major cytokines. Although the exact molecular mechanisms underlying the repression function of GR on NF-B activity are not fully understood, experimental evidence suggests that it is primarily the ligand-induced physical interaction between GR and DNA-bound NF-B subunits (RelA and p50) that ultimately inhibits NF-B activity [231–236]. The regulation of NF-B activity via the interaction between GR and NF-B subunits seems to be independent on GR DNA binding and homodimerization [236–238]. Although there is a consensus among researchers that the GR-mediated regulation of NF-B signaling takes place in the nucleus, it was proposed that ligand-induced activation of GR by glucocorticoids may regulate NF-B signaling in the cytoplasm by increasing IB protein level in HeLa cells, monocytic cells, and T cells [239, 240]. However, induction of IB seems to be cell type-specific mechanism underlying GR-mediated repression of NF-B activity since glucocorticoid treatment caused inhibition of NF-B activity without any detectable change in IB expression in endothelial cells  or epithelial cells [242, 243]. In an in vitro study involving human pulmonary epithelial A549 cells, monkey COS-1 cells, and human breast cancer T47D cells, it was shown that GR-mediated inhibition of NF-B activity occurs via a dual mechanism involving both protein-protein interaction between GR and NF-B subunits and induction of IB expression; with the former mechanism being predominant in NF-B regulation . Moreover, it seems that GR-mediated repression of NF-B activity via IB induction is not only cell type-specific, but it is also dependent on the type of ligand, the NF-B target gene, the presence of certain cofactors, the status of chromatin, and probably other conditions [221, 242, 245].
Noteworthy, other mechanisms underlying GR-mediated repression of NF-B activity have been proposed. For example, GR activation was shown to be associated with suppression of histone acetylase (HAT) activity via inhibited recruitment of large coactivator complexes containing HAT regulatory proteins such as CREB-binding protein (CBP) and p300 . Moreover, GR activation was shown to cause induced expression of histone deacetylase 2 (HDAC2) accompanied by recruitment of GR to NF-B target genes leading to their transrepression . It seems that the concentration of glucocorticoids is one determining factor in controlling the balance between GR-mediated suppression of HAT activity and induction of HDAC activity leading to modulated NF-B activity . Interestingly, GR itself is subject to deacetylation by HDAC2, which leads to GR nuclear translocation and physical interaction with NF-B subunits . It is also documented that induced histone methylation, rather than suppressed histone acetylation, may serve as a mechanism that underlies GR-mediated repression of NF-B functions [248, 249]. Additionally, experimental evidence revealed that attenuation of GR-mediated transrepression of its target genes is accompanied by recruitment of potent corepressors such as nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid hormone receptor (SMRT) [250–253]. Furthermore, it was proposed that GR interferes with NF-B-dependent serine phosphorylation of the C-terminal domain of RNA polymerase II leading to suppressed expression of NF-B target genes . These findings suggest that GR activation may repress NF-B activity without influencing NF-B DNA binding potential. Consistent with this proposal, treatment of asthmatic patients with inhaled glucocorticoids suppresses inflammation via inhibition of NF-B-mediated expression of inflammatory mediators with no detectable reduction in NF-B DNA binding ability . Together, these findings strongly suggest that GR can modulate NF-B activity in the nucleus by regulating several key events including NF-B DNA binding, HAT and/or HDAC expression, coactivator(s) and/or corepressor(s) recruitment, as well as RNA polymerase II-induced transactivation of NF-B target genes. Finally, glucocorticoids may serve as inhibitors of NF-B activity via their ability to modulate the activity of proteins involved in the mitogen-activated protein kinase (MAPK) pathways including c-jun N-terminal kinase (JNK), p38, and MAP kinase phosphatase-1 (MKP-1), all of which can cross-talk and modulate NF-B activity, and thus, inflammatory responses [255–263].
14. AEBP1 Is a Multifunctional Protein
Adipocyte enhancer-binding protein-1 (AEBP1) is a ubiquitously expressed protein whose expression seems to be the highest in adipose tissue, liver, lung, spleen, and brain . Recently, AEBP1 was shown to be abundantly expressed in primary macrophages as well as macrophage cell lines [265–267]. AEBP1 shares a remarkable amino acid sequence homology with two members of the regulatory carboxypeptidase family of enzymes, CPX1 and CPX2, all of which contain N-terminal discoidin-like domain (DLD) and homologous central carboxypeptidase (CP) domain . Unlike CPX1 and CPX2, which are catalytically inactive [269, 270], AEBP1 functions as an active carboxypeptidase capable of catalyzing hydrolysis of arginine and lysine in hippuryl-arg and hippuryl-lys synthetic carboxypeptidase B (CPB) substrates, respectively [271, 272]. Studies from Ro’s laboratory have demonstrated that deletion of residues 429 to 460 in the CP domain, which encompasses the active site, renders AEBP1 catalytically inactive . Moreover, the carboxypeptidase activity of AEBP1 has been shown to be responsive to carboxypeptidase activators and inhibitors, and that DNA binding enhances AEBP1 hydrolytic activity , indicating that AEBP1 functions as an active carboxypeptidase.
AEBP1 is highly expressed in preadipocytes, and its expression persists during the first stages of adipogenesis [271, 273]. However, AEBP1 levels drop dramatically as preadipocytes differentiate into mature adipocytes, and AEBP1 expression is completely abolished in terminally differentiated, nonproliferative adipocytes [264, 271, 273]. Because of the altered expression pattern of AEBP1 during adipogenesis, AEBP1 was suspected to play a negative regulatory role in adipose P2 (aP2) expression in preadipocytes. Indeed, in vitro studies have demonstrated that AEBP1 specifically binds adipocyte enhancer-1 (AE-1) DNA sequence , and transcriptionally represses aP2 in 3T3-L1 preadipocytes and other cell lines [271, 273, 274]. Transcriptional repression of aP2 by AEBP1 is physiologically significant since targeted over-expression of AEBP1 in adipose tissue causes diet-induced obesity in mice . AEBP1 seems to induce massive obesity in mice with targeted, tissue-specific overexpression of AEBP1 ( mice) by inducing adipocyte proliferation in vivo, leading to adipocyte hyperplasia in white adipose tissue . In contrast, AEBP1-deficient mice ( mice) display 25% reduction in total body weight due to significantly reduced fat pads caused by enhanced apoptosis and impaired survival signal . Indeed, preadipocytes display augmented proliferation [273, 275], while preadipocytes exhibit a defective proliferative potential in vitro .
MAPK pathways are a network of serine/threonine kinases and dual-specificity kinases, whose function is implicated in various key biological processes in the cell including proliferation, inflammation, and tumorigenesis [277–280]. Kinases involved in MAPK pathways include JNK1/2, extracellular signal-regulated kinases 1 and 2 (ERK1/2), and other MAP kinases (e.g., MEK, MEKK, and MEKKK). In vitro and in vivo experimental studies revealed that AEBP1 physically interacts with ERK1/2 via its DLD . This protein-protein interaction is critical for MAPK activity since it leads to protection of ERK1/2 from dephosphorylation by its specific phosphatase (MKP-3), leading to sustained activation of ERK1/2 . AEBP1 inhibits differentiation of preadipocytes into mature adipocytes, thus impeding adipogenesis, by means of enhancing ERK1/2 activity in preadipocytes .
Recently, AEBP1 was shown to be a critical regulator of macrophage cholesterol homeostasis, foam cell formation, and macrophage inflammatory responsiveness . In fact, AEBP1 was shown to manifest its proinflammatory effects by promoting NF-B activity via impeding the inhibitory function of IB in macrophages, an event that seems to be dependent on AEBP1-IB physical interaction . Most recently, experimental evidence indicates that AEBP1 mediates LPS-induced foam cell formation by virtue of its ability to directly suppress peroxisome proliferator-activated receptor 1 (PPAR1) and liver X receptor (LXR) activity in macrophages, suggesting that AEBP1 may play a critical regulatory role in bacterial infection-induced atherosclerosis .
15. DLD Mediates AEBP1-IB Interaction
The N-terminus of AEBP1 contains DLD that is remarkably homologous to discoidin, a lectin expressed in the slime mold Dictyostelium discoideum , and hence the name. In Dictyostelium discoideum, discoidin has been shown to be crucial for proper cell aggregation and migration  as well as protein-protein interaction [283, 284]. Indeed, DLD of AEBP1 was found to be required for protein-protein interaction between AEBP1 and MAPK . Similarly, it was shown that AEBP1 is capable of physically interacting with IB by means of its DLD, whose deletion eliminated AEBP1-IB interaction . It is worth mentioning that despite the structural similarities between IB and IB, co-immunoprecipitation experiments suggest that AEBP1 is capable of interacting with IB, but not IB, in macrophages . Analysis of IB-IB amino acid sequence alignment reveals that there are three main structural differences between IB and IB (Figure 4). First, the first 12 amino acid residues in IB are absent in IB. Second, there is a 41-amino acid stretch located between the third and forth ANK repeat of IB that is not present in IB. Third, there is an 18-amino acid stretch at the C-terminus of IB that is absent in IB. Based on sequence analysis, it is conceivable that either the presence of the first 12 amino acid residues in IB is required for interaction with AEBP1 or that the presence of the extra-amino acid stretches in IB allows the formation of a tertiary structure that does not permit protein-protein interaction with AEBP1. It is also conceivable that the extra-amino acid stretches in IB somehow mask the region, or domain, that is necessary for protein-protein interaction with AEBP1. We are currently attempting to map the exact region of IB that mediates protein-protein interaction with AEBP1, which will shed more light on the differential ability of AEBP1 to regulate IB and IB functions. Further investigation of the AEBP1-interacting region of IB will shed more light on how AEBP1 is capable of differentially regulating IB and IB functions in vivo. Although modulation of IB expression has been previously shown to be a mechanism explaining altered NF-B activity [285–287], the data we have recently demonstrated is the first of its kind to propose a molecular mechanism behind modulated NF-B activity by which IB protein stability is altered via protein-protein interaction and is independent of alterations in IKK complex kinetic activity .
Since about 50% of AEBP1 protein population exists in the nucleus [266, 288], and since newly synthesized IB is known to translocate to the nucleus to bind DNA-bound NF-B dimers and resequester them into the cytosol , it is possible that AEBP1 and IB interact in the nucleus. This is an interesting possibility since AEBP1-IB interaction in the nucleus can interfere with the ability of nuclear IB to bind to its target, DNA-bound NF-B dimers, leading to sustained NF-B-driven transactivation of target genes (e.g., proinflammatory genes). Thus, by virtue of its cytosolic/nuclear localization and its ability to bind IB, it is reasonable to propose that AEBP1 can impede IB inhibitory functions towards NF-B both at the cytosolic and nuclear levels.
Noteworthy, DLD has been identified in several extracellular and intracellular proteins including discoidin domain receptor tyrosine kinase (DDR) , the blood coagulation cofactors V and VIII , milk-fat globule proteins , muskelin , retinoschisin , and developmental endothelial locus-1 (Del-1) . It would be of great interest to assess whether such DLD-containing proteins have the potential to physically interact with IB, as does AEBP1. Such assessment coupled with careful analysis of the amino acid variations among the DLD sequences of these proteins will assist in mapping the exact amino acid stretch within DLD that mediates interaction with IB.
16. DLD Mediates AEBP1 Protein-Protein Interaction with Other Proteins
DLD has been suggested to mediate cell-cell adhesion , protein self-association , and protein-protein interaction [283, 284]. In fact, protein-protein interaction between AEBP1 and MAPK in the cytosol, which prolongs MAPK activation by protecting it from dephosphorylation by its specific phosphatase (MKP-3, also known as PYST1), has been shown to be mediated by DLD of AEBP1 . Similarly, AEBP1 was shown to be capable of physically interacting with cytosolic IB via its DLD, whose deletion eliminates AEBP1-IB protein-protein interaction . So, these findings further support a role of DLD in protein-protein interaction in mammalian systems. Furthermore, these findings underscore the importance of DLD in mediating very critical functions undertaken by AEBP1 to control key biological processes in the cell. Intriguingly, we propose that the presence of DLD creates a molecular competition between MAPK and IB in the cytosol to bind to AEBP1. This proposal is interesting given that sustained MAPK activation and IB proteolytic degradation followed by NF-B activation culminate in diverse biological outcomes in different cell types. Although the molecular mechanisms that signal AEBP1 to interact predominantly with MAPK or IB are unknown, it is conceivable that AEBP1 can be utilized by the cell as an on/off switch to promote or inhibit MAPK and NF-B activities via balancing AEBP1 protein-protein interaction with MAPK and IB.
17. AEBP1 and NF-B: A Positive Relationship
Since its initial identification by Sen and Baltimore about two decades ago , NF-B has been the focus of many researchers in an attempt to understand the various molecular mechanisms involved in inflammatory diseases and cancer. Modulation of NF-B activity can result in many abnormal cellular processes and diseases including asthma, arthritis, atherosclerosis, obesity, and various types of cancers [2–7]. Recently, we have provided experimental evidence establishing a positive relationship between AEBP1 expression and NF-B activity in macrophages . Nuclear p65 protein level was shown to be barely detectable in macrophages, compared to counterparts . Consistently, electrophoretic mobility gel shift assay clearly illustrates that ablation of AEBP1 expression in macrophages correlates with inhibited NF-B DNA-binding activity . This positive relationship seems to be a consequence of a negative relationship between AEBP1 expression and IB protein stability in macrophages. Interestingly, AEBP1 was shown to promote IB phosphorylation followed by its proteolytic degradation, liberating the NF-B subunits, which translocate into the nucleus and become transcriptionally active . Furthermore, this negative regulation imposed by AEBP1 on IB function in the cytosol seems to be mediated by protein-protein interaction that requires DLD of AEBP1, as confirmed by co-immunoprecipitation analysis . Consistent with the proposal that AEBP1-IB protein-protein interaction, which is mediated by DLD, provokes destabilization of IB shortening its half-life, the N-terminus deletion (N) and carboxypeptidase (CP) mutant forms of AEBP1, which are devoid of DLD, have no influence on IB protein stability, unlike AEBP1 derivatives retaining DLD . Importantly, in contrast to the WT form of AEBP1, N and CP mutant forms possess marginal or no upregulatory function towards NF-B activity , confirming that AEBP1-IB interaction is a key biological event that is crucial for AEBP1-mediated IB-induced degradation and subsequent NF-B up-regulation in macrophages.
It is known that alteration of IKK kinetic activity ultimately leads to modulation of IB phosphorylation and proteolytic degradation . Given that AEBP1 regulates IB phosphorylation status and its proteolytic degradation, one may speculate that AEBP1 is capable of modulating IB function in macrophages by means of altering the kinetic potential of IKK. However, this possibility was ruled out by in vitro kinase assays demonstrating that IKK kinetic activity against a bacterially expressed GST-IB (aa 1-54) fusion protein is comparable in and macrophages under both basal and LPS-stimulatory conditions . In addition, it was shown that AEBP1 is not a component of the IKK complex nor it influences the composition of the IKK complex in macrophages .
In a recent report, we have hypothesized that the positive regulatory role that AEBP1 imposes on NF-B activity may not be macrophage specific . In fact, abrogation of NF-B activity has been shown to cause embryonic lethality due to liver apoptosis [25, 26, 164]. If AEBP1-mediated positive regulation of NF-B is a universal process that takes place in cells and tissues other than macrophages (e.g., liver), one would expect that embryos may suffer from liver apoptosis that is life-threatening. Although NF-B activity has not been evaluated in hepatocytes, it is fascinating that mice suffer from about 50% embryonic lethality . Hence, severe diminishment of NF-B activity, which can potentially lead to liver apoptosis, that is caused by AEBP1 deficiency may serve as a molecular mechanism underlying embryonic lethality in mice. Interestingly, our recent findings reveal that the levels of the apoptotic markers p-STAT3 and cleaved caspase-3 are significantly higher in the livers of mice compared to control mice (unpublished), suggesting that AEBP1 plays an antiapoptotic role in vivo. Consistent with its ability to promote NF-B activity in various cell types, preliminary findings suggest that AEBP1 also promotes NF-B activity in mammary gland tissue, in which NF-B activity is significantly enhanced and diminished in the mammary gland tissues obtained from mice that over-express and lack AEBP1, respectively (unpublished). In sum, AEBP1-mediated promotion of NF-B activity seems to be a regulatory event that occurs in various cells and tissues.
18. Differential Regulation of IB and IB: A Possible Role for AEBP1?
Despite their structural homology, individual IB proteins have distinctive structural features and they exhibit differential ability and preference to associate with and inhibit various combinations of NF-B dimers in the cytosol. For example, both IB and IB preferentially interact with and inhibit the activity of NF-B dimers containing p50, p65, and c-Rel [54, 123, 295], IB prefers p50 homodimers and p50/p65 heterodimers , IB prefers p65 and c-Rel homo- and heterodimers , and Bcl-3 prefers p50 and p52 homodimers [95, 298]; whereas p100 and p105 seem to bind to almost all possible dimer combinations of NF-B proteins [89, 299]. It is also known that different NF-B dimers display differential intrinsic preference with regard to DNA binding specificity [88, 300], and this DNA binding specificity confers distinct NF-B dimers a differential transactivation potential towards a diverse set of genes .
Additionally, IB and IB are known to be differentially regulated in various cell types and under several stimulatory conditions [143, 295]. Although both IB and IκB become ubiquitinated upon phosphorylation, the two lysine residues (Lys21 and Lys22) at the N-terminus of IκBα are required for ubiquitination; whereas the lysine residue (Lys9) at the N-terminus of IB is not required for ubiquitination . In addition, several studies have demonstrated that while IB is subject to rapid degradation upon cell stimulation by various stimuli including LPS, IL-1, TNF, and PMA in most cell types, IB degradation cannot be induced except by very few potent stimuli such as LPS and IL-1 in certain cell types and it tends to be a relatively slow process [147, 295]. However, other studies have shown that S19/S23-phosphorylated IB is subject to degradation induced by PMA or TNF treatment [143, 302]. The slower kinetics associated with IB degradation has been suggested to be probably due to the slower rate of IB phosphorylation by the IKK complex, which seems to favor IB as a more efficient substrate . So, depending on the potency of signals, IB may or may not become subject to phosphorylation and subsequent degradation . The differential ability of IKK to phosphorylate IB and IB has been suggested as a mechanism to explain the differential proteolytic degradation kinetics of IB and IB . Here, it can be argued that AEBP1, by virtue of its differential ability to interact with IB, but not IB, may play a determining role in making IB more susceptible than IB to signal-induced phosphorylation and subsequent degradation. Hence, AEBP1 physical interaction with IB, but not IB, has been proposed to serve as a mechanism that may elucidate the differential regulatory functions exhibited by these two molecules in vitro and in vivo .
Since the PEST domain plays a critical role in IB protein turnover/stability [52, 110, 143], it is arguable that the function of this domain is differentially regulated in IB and IB, thus leading to their differential regulation. However, studies have shown that deletion or mutations within the PEST domain confer resistance to signal-induced degradation for both IB [110, 115, 117, 189–191] and IB [143, 192–194]. In light of these results, understanding the role of PEST domain does not seem to help in explaining the differential regulation imposed on IB and IB. In addition, while the two N-terminal lysine residues (K21 and K22) of IB are known to be ubiquitination sites that are required for signal-induced degradation of IB [187, 188], the only N-terminal lysine residue (K9) in IB does not seem to be an exclusive ubiquitination site, and its mutation has no effect on signal-induced degradation of IB . Moreover, it was shown that IB is phosphorylated on Ser19 and Ser23 in unstimulated cells; whereas Ser32 and Ser36 phosphorylation in IB is only signal induced .
In sum, the differential specificity of IB/NF-B interaction combined with the differential transactivation potential of different NF-B dimers may explain how differential regulation of distinct IB proteins can lead to differential regulation of NF-B dimer activity, and thus, differential expression control of discrete genes. However, due to the remarkable similarities between IB and IB in terms of their structure and NF-B dimer specificity, understanding the molecular mechanisms behind the differential regulatory functions undertaken by these two molecules in different cell types and under different conditions has proven to be a tremendous challenge, and so far, a crystal-clear explanation of such differential regulation of these two molecules is still lacking.
19. AEBP1-IB Interaction Leads to IBDegradation: Unknown Mechanism
To date, two pathways have been suggested as molecular mechanisms responsible for IB proteolytic degradation. First, upon stimulation, IB is thought to be degraded via a classical, signal-induced proteasome-dependent pathway that involves the 26S proteasome . Second, in vitro studies using immature B cells have demonstrated that IB can be subject to constitutive proteasome-independent, Ca++-dependent degradation under basal conditions . It was also shown that constitutive phosphorylation of serine/threonine residues within the C-terminal PEST domain of IB by CKII is required for IB turnover [111–113]. Also, accumulation of free IB in the cytosol triggers its rapid degradation through a phosphorylation, ubiquitination-independent proteasome-dependent pathway . The exact molecular mechanism(s) underlying the regulatory role of AEBP1 towards IB activity is not yet identified. However, we have questioned the molecular mechanisms by which AEBP1-IB interaction leads to IB phosphorylation and subsequent proteolytic degradation, and three speculative points regarding such molecular mechanisms were offered . First, AEBP1-IB interaction could cause a conformational change in the latter rendering it more susceptible to Ser32/Ser36 phosphorylation and degradation via the ubiquitination-dependent proteasome-dependent pathway. Second, IB-bound AEBP1 could serve as a recruiting scaffold protein that facilitates recruitment of the constitutive proteasome-independent Ca++-dependent proteolytic or ubiquitination-independent proteasome-dependent machineries. Third, it is possible that AEBP1-bound IB is more prone to constitutive phosphorylation on serine/threonine residues within the PEST domain, inducing its proteasome-dependent proteolytic degradation. Here, we speculate that AEBP1 may also serve as a “bridge” that brings IB in proximity to IKK/ in the cytosol, forcing IB phosphorylation and subsequent proteolytic degradation. In addition, it is possible that AEBP1 somehow enhances the catalytic activity of an “unknown” kinase that can potentially phosphorylate S32 and S36 in IB. Moreover, one may speculate that AEBP1 interferes with an “unknown” phosphatase that exercises its catalytic activity on S32/S36-phosphorylated IB in the cytosol. Finally, AEBP1 interaction with IB may protect the latter from sumoylation, favoring its ubiquitination and subsequent proteolytic degradation. Examination of these possibilities may shed light on the exact molecular mechanism undertaken by AEBP1 to hamper IB inhibitory function towards NF-B.
20. AEBP1-Mediated NF-B Upregulation Is Independent of PPAR1 and LXRModulation
Experimental evidence suggesting that PPAR1 and LXR play anti-inflammatory roles is overwhelming. PPAR and LXR ligands suppress inflammation by interfering with the NF-B, AP-1, and STAT signaling pathways [303–312]. PPAR1 and LXR repression by AEBP1 serves as a mechanism that satisfactorily explains the proinflammatory properties exhibited by AEBP1 in macrophages. Since AEBP1 represses PPAR1 and LXR transcriptional activity in macrophages [265, 267], active PPAR1 and LXR interfere with NF-B activity [303, 304, 307, 313], and AEBP1 enhances NF-B activity, it is reasonable to suggest that PPAR1 and LXR transcriptional repression by AEBP1 may contribute to AEBP1-mediated NF-B up-regulation in macrophages. However, this effect may be negligible since deletion of DLD, which does not influence the ability of AEBP1 to repress PPAR1 or LXR , completely eliminates the ability of AEBP1 to up-regulate NF-B activity . In agreement, deletion of the C-terminus of AEBP1, which completely eliminates the ability of AEBP1 to repress PPAR1 or LXR , does not interfere with the ability of AEBP1 to up-regulate NF-B activity . Additionally, Glass and colleagues have shown that neither treatment of RAW 264.7 macrophages with PPAR ligand nor PPAR1 overexpression in absence of its ligand had any anti-inflammatory effects . Rather, PPAR-mediated anti-inflammatory effects are only observed when PPAR1 is over-expressed and ligand activated . Similarly, LXR-mediated anti-inflammatory effects can only be observed in the presence of LXR ligands and under LPS-stimulatory conditions . However, AEBP1 was shown to enhance NF-B activity in macrophages expressing endogenous PPAR1 and LXR in the absence of PPAR or LXR ligands under both basal and LPS-stimulatory conditions . Collectively, we conclude that co-ordinate AEBP1-mediated IB proteolytic degradation and subsequent NF-B up-regulation is independent of AEBP1-mediated PPAR1 and LXR repression in macrophages.
21. Potential Role of AEBP1 in Septic Shock Syndrome
Septic shock syndrome is a very serious medical condition that can lead to failure of many body organs, eventually causing death. Septic shock is caused by an exaggerated immune response against the LPS component of various Gram-negative bacteria via TLR signaling [320, 321]. Very recently, LPS was shown to significantly induce AEBP1 expression in macrophages, and that LPS-induced down-regulation of the pivotal anti-inflammatory mediators PPAR1 and LXR is largely mediated by AEBP1 . Given the role that AEBP1 plays in LPS signaling in macrophages, and given AEBP1 role in inducing macrophage proinflammatory responsiveness  via promoting NF-B activity in macrophages , it is conceivable that mice may be resistant to LPS-induced septic shock and Gram-negative bacterial infection-induced atherosclerosis. In contrast, mice with targeted overexpression of AEBP1 in adipose tissue and macrophages  are expected to be more susceptible to LPS-induced septic shock and Gram-negative bacterial infection-induced atherosclerosis compared to their WT counterparts. It would be very intriguing to investigate the susceptibility of and mice to develop septic shock syndrome upon administration of pathogenic Gram-negative bacteria such as C. pneumonia.
22. Other IB-Interacting Proteins and Modulation of NF-B Activity
Recently, very few studies have proposed that protein-protein interactions involving IB may serve as a molecular mechanism explaining the potential of some proteins to modulate NF-B activity in vitro and in vivo. Besides NF-B subunits, only a handful of proteins have been shown to physically interact with IB using yeast two-hybrid system or co-immunoprecipitation experiments. The X protein of hepatitis B virus (HBV) has been shown to physically interact with IB, but not IB, and this interaction leads to sustained NF-B activation following TNF treatment . Mutagenesis analysis revealed that the 249-253 amino acid sequence towards the C-terminus of IB is critical for protein-protein interaction between X protein and IB . Human -arrestin2, a cytosolic protein that is expressed predominantly in the spleen and neuronal tissue, has been shown to directly interact with IB leading to inhibited phosphorylation and degradation of IB, ultimately leading to NF-B down-regulation . The first 60 amino acids within the N-terminus of -arrestin2 comprise the IB interacting region, and the C-terminal domain (40 amino acids) of IB contributes to the -arrestin2 binding . Using GST fusion protein pull-down assays, the poxvirus and zinc finger (POZ) domain at the N-terminus of FBI-1 (factor that binds to the inducer of short transcripts of human immunodeficiency virus-1), a ubiquitously expressed nuclear protein, has been shown to mediate protein-protein interaction between FBI-1 and IB . Additionally, ChlaDub1 is a deubiquitinating protease from Chlamydia trachomatis that has been shown to physically interact with IB, leading to impaired ubiquitination and proteolytic degradation of IB and blocked NF-B activation in transfected HeLa and HEK293N cells . Similarly, human G protein-coupled receptor kinase 5 (GRK5), a protein that is highly expressed in the heart, placenta, lung and skeletal muscle, has been shown to interact with IB in BAEC and HEK293 cells . GRK5-IB interaction has been shown to enhance nuclear accumulation of IB, ultimately causing diminished NF-B-driven transcription and NF-B DNA binding . The regulator of gene protein signaling homology domain of GRK5 (RH) and the N-terminal domain of IB have been identified as the regions involved in GRK5-IB interaction . Finally, a yeast two-hybrid screen of a human library and co-immunoprecipitation experiments have recently revealed that N-terminal protease () of classical swine fever virus (CSFV), a protein that is localized in the cytosolic and nuclear compartments, physically interacts with IB leading to transient nuclear accumulation of pIB in the infected porcine kidney cell line PK-15 . Yet, NF-B activation does not seem to be significantly affected in PK-15 cells that were stably transfected with . It seems that the C-terminal (aa 213-317) region of IB is essential for -IB interaction .
To date, however, AEBP1 is the only protein that was shown to be an interacting partner of IB in macrophages, and AEBP1-IB interaction seems to be physiologically significant with regard to NF-B transactivation and macrophage inflammatory responsiveness . In an attempt to identify a consensus sequence that may be responsible of mediating protein-protein interaction between the IB-interacting proteins mentioned above and IB, the amino acid sequences of the IB-interacting regions within these proteins were compared. Amino acid sequence analysis revealed that there is no obvious consensus sequence or considerable similarities within the identified IB-interacting regions of AEBP1, FBI-1, -arrestin2, and GRK5. Since the exact region of IB that mediates physical interaction between IB and these proteins is either different or unknown, it is difficult to search for other potential, yet unknown, IB-interacting protein based on amino acid sequence similarities. The so-far identified IB-interacting proteins and the domains/sequences involved in such interactions are outlined in Table 1.
NF-B signaling is critically involved in various biological processes that are crucial for cell growth and survival. The role that NF-B plays in inflammatory reactions cannot be underestimated. By virtue of its ability to act as a direct interacting partner of IB via its DLD, AEBP1 exerts a potent upregulatory function toward NF-B activity in macrophages. Hence, AEBP1 manifests itself as a critical modulator of inflammatory responses. Finally, we anticipate that AEBP1 may serve as a likely molecular target towards the development of novel therapeutic strategies for the prevention or treatment of various inflammatory disorders such as atherosclerosis and septic shock syndrome.
|AEBP1:||Adipocyte enhancer-binding protein-1|
|cAMP:||Cyclic adenosine monophosphate|
|CKII:||Casein kinase II|
|ELKS:||Glutamic acid, leucine, lysine, and serine-rich protein|
|ERK:||Extracellular signal-regulated kinase|
|FBI-1:||Factor that binds to the inducer of short transcripts of HIV-1|
|GRK:||G protein-coupled receptor kinase 5|
|GST:||Glutathione S transferase|
|ICAM-1:||Intracellular adhesion molecule-1|
|IB:||Inhibitor of NF-B|
|iNOS:||Inducible nitric oxide synthase|
|IRAK:||Interleukin 1 receptor-associated kinase|
|JNK:||C-jun N-terminal kinase|
|LXR:||Liver X receptor|
|MAPK:||Mitogen-activated protein kinase|
|MCP-1:||Monocyte chemoattractant protein-1|
|MEKK:||MEK kinase (also designated as MAPKKK)|
|MKP:||MAP kinase phosphatase|
|NCoR:||Nuclear receptor co-repressor|
|NEMO:||NF-B essential modulator|
|NES:||Nuclear export signal|
|NF-B:||Nuclear factor kappa B|
|NIK:||NF-B inducing kinase|
|NLS:||Nuclear localization signal|
|oxLDL:||Oxidized low density lipoprotein|
|PIASy:||Protein inhibitor of activated STATy|
|PKA:||Protein kinase A|
|PKB/AKT:||Protein kinase B|
|PKC:||Protein kinase C|
|POZ:||Poxvirus and zinc finger domain|
|PPAR1:||Peroxisome proliferator-activated receptor 1|
|RHD:||Rel homology domain|
|RIP:||Receptor interacting protein|
|SMRT:||Silencing mediator of retinoid and thyroid hormone receptor|
|STAT:||Signal transducer and activator of transcription|
|SUMO:||Small ubiquitin-like modifier|
|TNF:||Tumor necrosis factor|
|TRADD:||TNF receptor-associated death domain|
|TRAF:||TNFR associated factor|
|VCAM-1:||Vascular cell adhesion molecule-1|
- P. A. Baeuerle, “Pro-inflammatory signaling: last pieces in the NF-B puzzle?” Current Biology, vol. 8, no. 1, pp. R19–R22, 1998.
- P. P. Tak and G. S. Firestein, “NF-B: a key role in inflammatory diseases,” Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001.
- Y. Yamamoto and R. B. Gaynor, “Therapeutic potential of inhibition of the NF-B pathway in the treatment of inflammation and cancer,” Journal of Clinical Investigation, vol. 107, no. 2, pp. 135–142, 2001.
- S. E. Shoelson, J. Lee, and M. Yuan, “Inflammation and the IKK/IB/NF-B axis in obesity- and diet-induced insulin resistance,” The International Journal of Obesity, vol. 27, supplement 3, pp. S49–S52, 2003.
- H. Clevers, “At the crossroads of inflammation and cancer,” Cell, vol. 118, no. 6, pp. 671–674, 2004.
- A. Kumar, Y. Takada, A. M. Boriek, and B. B. Aggarwal, “Nuclear factor-B: its role in health and disease,” The Journal of Molecular Medicine, vol. 82, no. 7, pp. 434–448, 2004.
- C. Monaco and E. Paleolog, “Nuclear factor B: a potential therapeutic target in atherosclerosis and thrombosis,” Cardiovascular Research, vol. 61, no. 4, pp. 671–682, 2004.
- P. A. Baeuerle and D. Baltimore, “IB: a specific inhibitor of the NF-B transcription factor,” Science, vol. 242, no. 4878, pp. 540–546, 1988.
- M. J. May and S. Ghosh, “Rel/NF-B and IB proteins: an overview,” Seminars in Cancer Biology, vol. 8, no. 2, pp. 63–73, 1997.
- S. Ghosh, M. J. May, and E. B. Kopp, “NF-B and Rel proteins: evolutionarily conserved mediators of immune responses,” Annual Review of Immunology, vol. 16, pp. 225–260, 1998.
- J. N. Wilcox, K. M. Smith, S. M. Schwartz, and D. Gordon, “Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 8, pp. 2839–2843, 1989.
- P. Barath, M. C. Fishbein, J. Cao, J. Berenson, R. H. Helfant, and J. S. Forrester, “Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization,” American Journal of Pathology, vol. 137, no. 3, pp. 503–509, 1990.
- K. Brand, B. J. Fowler, T. S. Edgington, and N. Mackman, “Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide,” Molecular and Cellular Biology, vol. 11, no. 9, pp. 4732–4738, 1991.
- M. I. Cybulsky and M. A. Gimbrone Jr., “Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis,” Science, vol. 251, no. 4995, pp. 788–791, 1991.
- N. Mackman, K. Brand, and T. S. Edgington, “Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor B binding sites,” Journal of Experimental Medicine, vol. 174, no. 6, pp. 1517–1526, 1991.
- R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993.
- P. A. Baeuerle and T. Henkel, “Function and activation of NF-B in the immune system,” Annual Review of Immunology, vol. 12, pp. 141–179, 1994.
- E. B. Kopp and S. Ghosh, “NF-B and Rel proteins in innate immunity,” Advances in Immunology, vol. 58, pp. 1–27, 1995.
- A. S. Baldwin Jr., “The NF-B and IB proteins: new discoveries and insights,” Annual Review of Immunology, vol. 14, pp. 649–683, 1996.
- T. Yokoo and M. Kitamura, “Dual regulation of IL-1-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-B and AP-1,” American Journal of Physiology, vol. 270, pp. F123–F130, 1996.
- J. A. Mengshol, M. P. Vincenti, C. I. Coon, A. Barchowsky, and C. E. Brinckerhoff, “Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor B: differential regulation of collagenase 1 and collagenase 3,” Arthritis and Rheumatism, vol. 43, no. 4, pp. 801–811, 2000.
- W. C. Sha, H. C. Liou, E. I. Tuomanen, and D. Baltimore, “Targeted disruption of the p50 subunit of NF-B leads to multifocal defects in immune responses,” Cell, vol. 80, no. 2, pp. 321–330, 1995.
- J. H. Caamaño, C. A. Rizzo, S. K. Durham et al., “Nuclear factor (NF)-B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses,” Journal of Experimental Medicine, vol. 187, no. 2, pp. 185–196, 1998.
- G. Franzoso, L. Carlson, L. Poljak et al., “Mice deficient in nuclear factor (NF)-B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture,” Journal of Experimental Medicine, vol. 187, no. 2, pp. 147–159, 1998.
- A. A. Beg, W. C. Sha, R. T. Bronson, S. Ghosh, and D. Baltimore, “Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-B,” Nature, vol. 376, no. 6536, pp. 167–170, 1995.
- T. S. Doi, T. Takahashi, O. Taguchi, T. Azuma, and Y. Obata, “NF-B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses,” Journal of Experimental Medicine, vol. 185, no. 5, pp. 953–961, 1997.
- E. Alcamo, J. P. Mizgerd, B. H. Horwitz et al., “Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-B in leukocyte recruitment,” Journal of Immunology, vol. 167, no. 3, pp. 1592–1600, 2001.
- F. Kontgen, R. J. Grumont, A. Strasser et al., “Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression,” Genes & Development, vol. 9, no. 16, pp. 1965–1977, 1995.
- F. Weih, D. Carrasco, S. K. Durham et al., “Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-B/Rel family,” Cell, vol. 80, no. 2, pp. 331–340, 1995.
- K. Brand, S. Page, G. Rogler et al., “Activated transcription factor nuclear factor-B is present in the atherosclerotic lesion,” Journal of Clinical Investigation, vol. 97, no. 7, pp. 1715–1722, 1996.
- C. Kaltschmidt, B. Kaltschmidt, J. Lannes-Vieira et al., “Transcription factor NF-B is activated in microglia during experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 55, no. 1, pp. 99–106, 1994.
- F. Parhami, Z. T. Fang, A. M. Fogelman, A. Andalibi, M. C. Territo, and J. A. Berliner, “Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate,” Journal of Clinical Investigation, vol. 92, no. 1, pp. 471–478, 1993.
- H.-B. Peng, T. B. Rajavashisth, P. Libby, and J. K. Liao, “Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells,” Journal of Biological Chemistry, vol. 270, no. 28, pp. 17050–17055, 1995.
- T. B. Rajavashisth, H. Yamada, and N. K. Mishra, “Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL: involvement of nuclear factor-B,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 10, pp. 1591–1598, 1995.
- K. Brand, T. Eisele, U. Kreusel et al., “Dysregulation of monocytic nuclear factor-B by oxidized low-density lipoprotein,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 10, pp. 1901–1909, 1997.
- K. Brand, S. Page, A. K. Walli, D. Neumeier, and P. A. Baeuerle, “Role of nuclear factor-B in atherogenesis,” Experimental Physiology, vol. 82, no. 2, pp. 297–304, 1997.
- S. Wolfrum, D. Teupser, M. Tan, K. Y. Chen, and J. L. Breslow, “The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-B target genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18601–18606, 2007.
- R. Gareus, E. Kotsaki, S. Xanthoulea et al., “Endothelial cell-specific NF-B inhibition protects mice from atherosclerosis,” Cell Metabolism, vol. 8, no. 5, pp. 372–383, 2008.
- K. M. Kim, J. Y. Choi, S.-E. Yoo et al., “HMCO5, herbal extract, inhibits NF-B expression in lipopolysaccharide treated macrophages and reduces atherosclerotic lesions in cholesterol fed mice,” Journal of Ethnopharmacology, vol. 114, no. 3, pp. 316–324, 2007.
- L. Wang, C. Geng, L. Jiang et al., “The anti-atherosclerotic effect of olive leaf extract is related to suppressed inflammatory response in rabbits with experimental atherosclerosis,” European Journal of Nutrition, vol. 47, no. 5, pp. 235–243, 2008.
- J. Wang, R. Zhang, Y. Xu, H. Zhou, B. Wang, and S. Li, “Genistein inhibits the development of atherosclerosis via inhibiting NF-B and VCAM-1 expression in LDLR knockout mice,” Canadian Journal of Physiology and Pharmacology, vol. 86, no. 11, pp. 777–784, 2008.
- Y. Liu, F. Yan, Y. Liu et al., “Aqueous extract of rhubarb stabilizes vulnerable atherosclerotic plaques due to depression of inflammation and lipid accumulation,” Phytotherapy Research, vol. 22, no. 7, pp. 935–942, 2008.
- H. Li, M. Dai, and W. Jia, “Paeonol attenuates high-fat-diet-induced atherosclerosis in rabbits by anti-inflammatory activity,” Planta Medica, vol. 75, no. 1, pp. 7–11, 2009.
- V. H. Thourani, S. S. Brar, T. P. Kennedy et al., “Nonanticoagulant heparin inhibits NF-B activation and attenuates myocardial reperfusion injury,” American Journal of Physiology, vol. 278, no. 6, pp. H2084–H2093, 2000.
- H. Sasaki, P. S. Ray, L. Zhu, N. Galang, and N. Maulik, “Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: possible role of NFB,” Toxicology, vol. 155, no. 1–3, pp. 27–35, 2000.
- H. Sasaki, P. S. Ray, L. Zhu, H. Otani, T. Asahara, and N. Maulik, “Hypoxia/reoxygenation promotes myocardial angiogenesis via an NFB-dependent mechanism in a rat model of chronic myocardial infarction,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 2, pp. 283–294, 2001.
- M. Yoshiyama, T. Omura, K. Takeuchi et al., “Angiotensin blockade inhibits increased JNKs, AP-1 and NFB DNA-binding activities in myocardial infarcted rats,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 4, pp. 799–810, 2001.
- T. Izumi, Y. Saito, I. Kishimoto et al., “Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-B activation and alleviates myocardial ischemia/reperfusion injury,” Journal of Clinical Investigation, vol. 108, no. 2, pp. 203–213, 2001.
- M. Shimizu, M. Tamamori-Adachi, H. Arai, N. Tabuchi, H. Tanaka, and M. Sunamori, “Lipopolysaccharide pretreatment attenuates myocardial infarct size: a possible mechanism involving heat shock protein 70-inhibitory B complex and attenuation of nuclear factor B,” Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 5, pp. 933–941, 2002.
- C. Thiemermann, “Inhibition of the activation of nuclear factor B to reduce myocardial reperfusion injury and infarct size,” Cardiovascular Research, vol. 63, no. 1, pp. 8–10, 2004.
- L. Lu, S. S. Chen, J. Q. Zhang, F. J. Ramires, and Y. Sun, “Activation of nuclear factor-B and its proinflammatory mediator cascade in the infarcted rat heart,” Biochemical and Biophysical Research Communications, vol. 321, no. 4, pp. 879–885, 2004.
- I. M. Verma, J. K. Stevenson, E. M. Schwarz, D. van Antwerp, and S. Miyamoto, “Rel/NF-B/IB family: intimate tales of association and dissociation,” Genes & Development, vol. 9, no. 22, pp. 2723–2735, 1995.
- K. Kawakami, C. Scheidereit, and R. G. Roeder, “Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 13, pp. 4700–4704, 1988.
- P. A. Baeuerle and D. Baltimore, “A 65-D subunit of active NF-B is required for inhibition of NF-B by IB,” Genes & Development, vol. 3, no. 11, pp. 1689–1698, 1989.
- S. Ghosh, A. M. Gifford, L. R. Riviere, P. Tempst, G. P. Nolan, and D. Baltimore, “Cloning of the p50 DNA binding subunit of NF-B: homology to Rel and dorsal,” Cell, vol. 62, no. 5, pp. 1019–1029, 1990.
- U. Zabel, R. Schreck, and P. A. Baeuerle, “DNA binding of purified transcription factor NF-B. Affinity, specificity, dependence, and differential half-site recognition,” Journal of Biological Chemistry, vol. 266, no. 1, pp. 252–260, 1991.
- S.-M. Kang, A.-C. Tran, M. Grilli, and M. J. Lenardo, “NF-B subunit regulation in nontransformed CD T lymphocytes,” Science, vol. 256, no. 5062, pp. 1452–1455, 1992.
- D. Plaksin, P. A. Baeuerle, and L. Eisenbach, “KBF1 (p50 NF-B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells,” Journal of Experimental Medicine, vol. 177, no. 6, pp. 1651–1662, 1993.
- A. M. Brown, M. W. Linhoff, B. Stein et al., “Function of NF-B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-B/Rel subunits,” Molecular and Cellular Biology, vol. 14, no. 5, pp. 2926–2935, 1994.
- W. S. Blair, H. P. Bogerd, S. J. Madore, and B. R. Cullen, “Mutational analysis of the transcription activation domain of RelA: identification of a highly synergistic minimal acidic activation module,” Molecular and Cellular Biology, vol. 14, no. 11, pp. 7226–7234, 1994.
- P. Dobrzanski, R. P. Ryseck, and R. Bravo, “Both N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif,” Molecular and Cellular Biology, vol. 13, no. 3, pp. 1572–1582, 1993.
- S. Ghosh and D. Baltimore, “Activation in vitro of NF-B by phosphorylation of its inhibitor IB,” Nature, vol. 344, no. 6267, pp. 678–682, 1990.
- A. Israel, “The IKK complex: an integrator of all signals that activate NF-B?” Trends in Cell Biology, vol. 10, no. 4, pp. 129–133, 2000.
- M. S. Hayden and S. Ghosh, “Signaling to NF-B,” Genes & Development, vol. 18, no. 18, pp. 2195–2224, 2004.
- G. Mosialos, P. Hamer, A. J. Capobianco, R. A. Laursen, and T. D. Gilmore, “A protein kinase-A recognition sequence is structurally linked to transformation by p59(v-rel) and cytoplasmic retention of p68(c-rel),” Molecular and Cellular Biology, vol. 11, no. 12, pp. 5867–5877, 1991.
- J. L. Norris and J. L. Manley, “Selective nuclear transport of the Drosophila morphogen dorsal can be established by a signaling pathway involving the transmembrane protein Toll and protein kinase A,” Genes & Development, vol. 6, no. 9, pp. 1654–1667, 1992.
- M. Naumann and C. Scheidereit, “Activation of NF-B in vivo is regulated by multiple phosphorylations,” EMBO Journal, vol. 13, no. 19, pp. 4597–4607, 1994.
- C. C. H. Li, R. M. Dai, E. Chen, and D. L. Longo, “Phosphorylation of NF-B1-p50 is involved in NF-B activation and stable DNA binding,” Journal of Biological Chemistry, vol. 269, no. 48, pp. 30089–30092, 1994.
- C. C. H. Li, M. Korner, D. K. Ferris, E. Chen, R. M. Dai, and D. L. Longo, “NF-B/Rel family members are physically associated phosphoproteins,” Biochemical Journal, vol. 303, no. 2, pp. 499–506, 1994.
- H. Zhong, H. SuYang, H. Erdjument-Bromage, P. Tempst, and S. Ghosh, “The transcriptional activity of NF-B is regulated by the IB- associated PKAc subunit through a cyclic AMP-independent mechanism,” Cell, vol. 89, no. 3, pp. 413–424, 1997.
- L. Vermeulen, G. De Wilde, P. van Damme, W. Vanden Berghe, and G. Haegeman, “Transcriptional activation of the NF-B p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1),” EMBO Journal, vol. 22, pp. 1313–1324, 2003.
- H. Zhong, R. E. Voll, and S. Ghosh, “Phosphorylation of NF-B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300,” Molecular Cell, vol. 1, no. 5, pp. 661–671, 1998.
- H. Zhong, M. J. May, E. Jimi, and S. Ghosh, “The phosphorylation status of nuclear NF-B determines its association with CBP/p300 or HDAC-1,” Molecular Cell, vol. 9, no. 3, pp. 625–636, 2002.
- A. Duran, M. T. Diaz-Meco, and J. Moscat, “Essential role of RelA Ser311 phosphorylation by PKC in NF-B transcriptional activation,” EMBO Journal, vol. 22, no. 15, pp. 3910–3918, 2003.
- D. Wang, S. D. Westerheide, J. L. Hanson, and A. S. Baldwin Jr., “Tumor necrosis factor -induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II,” Journal of Biological Chemistry, vol. 275, no. 42, pp. 32592–32597, 2000.
- H. Sakurai, H. Chiba, H. Miyoshi, T. Sugita, and W. Toriumi, “IB kinases phosphorylate NF-B p65 subunit on serine 536 in the transactivation domain,” Journal of Biological Chemistry, vol. 274, no. 43, pp. 30353–30356, 1999.
- X. Jiang, N. Takahashi, N. Matsui, T. Tetsuka, and T. Okamoto, “The NF-B activation in lymphotoxin receptor signaling depends on the phosphorylation of p65 at serine 536,” Journal of Biological Chemistry, vol. 278, no. 2, pp. 919–926, 2003.
- A. M. O'Mahony, M. Montano, K. van Beneden, L.-F. Chen, and W. C. Greene, “Human T-cell lymphotropic virus type 1 tax induction of biologically active NF-B requires IB kinase-1-mediated phosphorylation of RelA/p65,” Journal of Biological Chemistry, vol. 279, no. 18, pp. 18137–18145, 2004.
- L. V. Madrid, M. W. Mayo, J. Y. Reuther, and A. S. Baldwin Jr., “Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-B through utilization of the IB kinase and activation of the mitogen-activated protein kinase p38,” Journal of Biological Chemistry, vol. 276, no. 22, pp. 18934–18940, 2001.
- N. Sizemore, S. Leung, and G. R. Stark, “Activation of phosphatidylinositol 3-kinase in response to interleukin- 1 leads to phosphorylation and activation of the NF-B p65/RelA subunit,” Molecular and Cellular Biology, vol. 19, no. 7, pp. 4798–4805, 1999.
- J. Bohuslav, L.-F. Chen, H. Kwon, Y. Mu, and W. C. Greene, “p53 induces NF-B activation by an IB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1,” Journal of Biological Chemistry, vol. 279, no. 25, pp. 26115–26125, 2004.
- F. Fujita, Y. Taniguchi, T. Kato et al., “Identification of NAP1, a regulatory subunit of IB kinase-related kinases that potentiates NF-B signaling,” Molecular and Cellular Biology, vol. 23, no. 21, pp. 7780–7793, 2003.
- H. Buss, A. Dorrie, M. L. Schmitz, E. Hoffmann, K. Resch, and M. Kracht, “Constitutive and interleukin-1-inducible phosphorylation of p65 NF-B at serine 536 is mediated by multiple protein kinases including IB kinase (IKK)-, IKK, IKK, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55633–55643, 2004.
- F. Logeat, N. Israel, R. Ten et al., “Inhibition of transcription factors belonging to the rel/NF-B family by a transdominant negative mutant,” EMBO Journal, vol. 10, no. 7, pp. 1827–1832, 1991.
- S. M. Ruben, R. Narayanan, J. F. Klement, C.-H. Chen, and C. A. Rosen, “Functional characterization of the NF-B p65 transcriptional activator and an alternatively spliced derivative,” Molecular and Cellular Biology, vol. 12, no. 2, pp. 444–454, 1992.
- P. A. Ganchi, S.-C. Sun, W. C. Greene, and D. W. Ballard, “A novel NF-B complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerization,” Molecular and Cellular Biology, vol. 13, no. 12, pp. 7826–7835, 1993.
- R.-P. Ryseck, J. Novotny, and R. Bravo, “Characterization of elements determining the dimerization properties of RelB and p50,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3100–3109, 1995.
- C. Kunsch, S. M. Ruben, and C. A. Rosen, “Selection of optimal B/Rel DNA-binding motifs: interaction of both subunits of NF-B with DNA is required for transcriptional activation,” Molecular and Cellular Biology, vol. 12, no. 10, pp. 4412–4421, 1992.
- N. R. Rice, M. L. MacKichan, and A. Israel, “The precursor of NF-B p50 has IB-like functions,” Cell, vol. 71, no. 2, pp. 243–253, 1992.
- P. Bressler, K. Brown, W. Timmer, V. Bours, U. Siebenlist, and A. S. Fauci, “Mutational analysis of the p50 subunit of NF-B and inhibition of NF-B activity by trans-dominant p50 mutants,” Journal of Virology, vol. 67, no. 1, pp. 288–293, 1993.
- P. A. Baeuerle and D. Baltimore, “Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-B transcription factor,” Cell, vol. 53, no. 2, pp. 211–217, 1988.
- U. Zabel and P. A. Baeuerle, “Purified human IB can rapidly dissociate the complex of the NF-B transcription factor with its cognate DNA,” Cell, vol. 61, no. 2, pp. 255–265, 1990.
- S. T. Whiteside and A. Israel, “IB proteins: structure, function and regulation,” Seminars in Cancer Biology, vol. 8, no. 2, pp. 75–82, 1997.
- G. Totzke, F. Essmann, S. Pohlmann, C. Lindenblatt, R. U. Janicke, and K. Schulze-Osthoff, “A novel member of the IB family, human IB, inhibits transactivation of p65 and its DNA binding,” Journal of Biological Chemistry, vol. 281, no. 18, pp. 12645–12654, 2006.
- Q. Zhang, J. A. Didonato, M. Karin, and T. W. Mckeithan, “BCL3 encodes a nuclear protein which can alter the subcellular location of NF-B proteins,” Molecular and Cellular Biology, vol. 14, no. 6, pp. 3915–3926, 1994.
- G. Franzoso, V. Bours, S. Park, M. Tomita-Yamaguchi, K. Kelly, and U. Siebenlist, “The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-B-mediated inhibition,” Nature, vol. 359, no. 6393, pp. 339–342, 1992.
- G. Franzoso, V. Bours, V. Azarenko et al., “The oncoprotein Bcl-3 can facilitate NF-B-mediated transactivation by removing inhibiting p50 homodimers from select B sites,” EMBO Journal, vol. 12, no. 10, pp. 3893–3901, 1993.
- J. Inoue, T. Takahara, T. Akizawa, and O. Hino, “Bcl-3, a member of the IB proteins, has distinct specificity towards the Rel family of proteins,” Oncogene, vol. 8, no. 8, pp. 2067–2073, 1993.
- S. Haskill, A. A. Beg, S. M. Tompkins et al., “Characterization of an immediate-early gene induced in adherent monocytes that encodes IB-like activity,” Cell, vol. 65, no. 7, pp. 1281–1289, 1991.
- N. Davis, S. Ghosh, D. L. Simmons et al., “Rel-associated pp40: an inhibitor of the Rel family of transcription factors,” Science, vol. 253, no. 5025, pp. 1268–1271, 1991.
- A. A. Beg and A. S. Baldwin Jr., “The IB proteins: multifunctional regulators of Rel/NF-B transcription factors,” Genes & Development, vol. 7, no. 11, pp. 2064–2070, 1993.
- L. Breeden and K. Nasmyth, “Similarity between cell-cycle genes of budding yeast and fission yeast and the Notch gene of Drosophila,” Nature, vol. 329, no. 6140, pp. 651–654, 1987.
- S. E. Lux, K. M. John, and V. Bennett, “Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins,” Nature, vol. 344, no. 6261, pp. 36–42, 1990.
- P. Michaely and V. Bennett, “The ANK repeat: a ubiquitous motif involved in macromolecular recognition,” Trends in Cell Biology, vol. 2, no. 5, pp. 127–129, 1992.
- J. Q. Davis and V. Bennett, “The anion exchanger and -ATPase interact with distinct sites on ankyrin in in vitro assays,” Journal of Biological Chemistry, vol. 265, no. 28, pp. 17252–17256, 1990.
- E. N. Hatada, A. Nieters, F. G. Wulczyn et al., “The ankyrin repeat domains of the NF-B precursor p105 and the protooncogene Bcl-3 act as specific inhibitors of NF-B DNA binding,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 6, pp. 2489–2493, 1992.
- J.-I. Inoue, L. D. Kerr, D. Rashid, N. Davis, H. R. Bose Jr., and I. M. Verma, “Direct association of pp40/IB with rel/NF-B transcription factors: role of ankyrin repeats in the inhibition of DNA binding activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4333–4337, 1992.
- P. A. Ganchi, S.-C. Sun, W. C. Greene, and D. W. Ballard, “IB/MAD-3 masks the nuclear localization signal of NF-B p65 and requires the transactivation domain to inhibit NF-B p65 DNA binding,” Molecular Biology of the Cell, vol. 3, no. 12, pp. 1339–1352, 1992.
- M. K. Ernst, L. L. Dunn, and N. R. Rice, “The PEST-like sequence of IB is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers,” Molecular and Cellular Biology, vol. 15, no. 2, pp. 872–882, 1995.
- P. Beauparlant, R. Lin, and J. Hiscott, “The role of the C-terminal domain of IB in protein degradation and stabilization,” Journal of Biological Chemistry, vol. 271, no. 18, pp. 10690–10696, 1996.
- J. A. McElhinny, S. A. Trushin, G. D. Bren, N. Chester, and C. V. Paya, “Casein kinase II phosphorylates IB at S-283, S-289, S-293, and T-291 and is required for its degradation,” Molecular and Cellular Biology, vol. 16, no. 3, pp. 899–906, 1996.
- R. Lin, P. Beauparlant, C. Makris, S. Meloche, and J. Hiscott, “Phosphorylation of IB in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability,” Molecular and Cellular Biology, vol. 16, no. 4, pp. 1401–1409, 1996.
- E. M. Schwarz, D. van Antwerp, and I. M. Verma, “Constitutive phosphorylation of IB by casein kinase II occurs preferentially at serine 293: requirement for degradation of free IB,” Molecular and Cellular Biology, vol. 16, no. 7, pp. 3554–3559, 1996.
- J. A. Brockman, D. C. Scherer, T. A. McKinsey et al., “Coupling of a signal response domain in IB to multiple pathways for NF-B activation,” Molecular and Cellular Biology, vol. 15, no. 5, pp. 2809–2818, 1995.
- K. Brown, S. Gerstberger, L. Carlson, G. Franzoso, and U. Siebenlist, “Control of IB- proteolysis by site-specific, signal-induced phosphorylation,” Science, vol. 267, no. 5203, pp. 1485–1488, 1995.
- E. B.-M. Traenckner, H. L. Pahl, T. Henkel, K. N. Schmidt, S. Wilk, and P. A. Baeuerle, “Phosphorylation of human IB- on serines 32 and 36 controls IB- proteolysis and NF-B activation in response to diverse stimuli,” EMBO Journal, vol. 14, no. 12, pp. 2876–2883, 1995.
- S. T. Whiteside, M. K. Ernst, O. LeBail, C. Laurent-Winter, N. Rice, and A. Israel, “N- and C-terminal sequences control degradation of MAD3/IB in response to inducers of NF-B activity,” Molecular and Cellular Biology, vol. 15, no. 10, pp. 5339–5345, 1995.
- T. Leveillard and I. M. Verma, “Diverse molecular mechanisms of inhibition of NF-B/DNA binding complexes by IB proteins,” Gene Expression, vol. 3, no. 2, pp. 135–150, 1993.
- C. Johnson, D. van Antwerp, and T. J. Hope, “An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IB,” EMBO Journal, vol. 18, no. 23, pp. 6682–6693, 1999.
- F. Arenzana-Seisdedos, P. Turpin, M. Rodriguez et al., “Nuclear localization of IB promotes active transport of NF-B from the nucleus to the cytoplasm,” Journal of Cell Science, vol. 110, no. 3, pp. 369–378, 1997.
- G. Ghosh, G. van Duyne, S. Ghosh, and P. B. Sigler, “Structure of NF-B p50 homodimer bound to a B site,” Nature, vol. 373, no. 6512, pp. 303–310, 1995.
- C. W. Muller, F. A. Rey, M. Sodeoka, G. L. Verdine, and S. C. Harrison, “Structure of the NF-B p50 homodimer bound to DNA,” Nature, vol. 373, no. 6512, pp. 311–317, 1995.
- A. A. Beg, S. M. Ruben, R. I. Scheinman, S. Haskill, C. A. Rosen, and A. S. Baldwin Jr., “IB interacts with the nuclear localization sequences of the subunits of NF-B: a mechanism for cytoplasmic retention,” Genes & Development, vol. 6, no. 10, pp. 1899–1913, 1992.
- T. Henkel, U. Zabel, K. van Zee, J. M. Muller, E. Fanning, and P. A. Baeuerle, “Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-B subunit,” Cell, vol. 68, no. 6, pp. 1121–1133, 1992.
- U. Zabel, T. Henkel, M. S. Silva, and P. A. Baeuerle, “Nuclear uptake control of NF-B by MAD-3, an IB protein present in the nucleus,” EMBO Journal, vol. 12, no. 1, pp. 201–211, 1993.
- P. Dobrzanski, R.-P. Ryseck, and R. Bravo, “Differential interactions of Rel-NF-B complexes with IB determine pools of constitutive and inducible NF-B activity,” EMBO Journal, vol. 13, no. 19, pp. 4608–4616, 1994.
- S. Simeonidis, D. Stauber, G. Chen, W. A. Hendrickson, and D. Thanos, “Mechanisms by which IB proteins control NF-B activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 1, pp. 49–54, 1999.
- H. Suyang, R. Phillips, I. Douglas, and S. Ghosh, “Role of unphosphorylated, newly synthesized IB in persistent activation of NF-B,” Molecular and Cellular Biology, vol. 16, no. 10, pp. 5444–5449, 1996.
- S.-C. Sun, P. A. Ganchi, D. W. Ballard, and W. C. Greene, “NF-B controls expression of inhibitor IB: evidence for an inducible autoregulatory pathway,” Science, vol. 259, no. 5103, pp. 1912–1915, 1993.
- Q. Cheng, C. A. Cant, T. Moll et al., “NF-B subunit-specific regulation of the IB promoter,” Journal of Biological Chemistry, vol. 269, no. 18, pp. 13551–13557, 1994.
- P. J. Chiao, S. Miyamoto, and I. M. Verma, “Autoregulation of IB activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 1, pp. 28–32, 1994.
- F. Arenzana-Seisdedos, J. Thompson, M. S. Rodriguez, F. Bachelerie, D. Thomas, and R. T. Hay, “Inducible nuclear expression of newly synthesized IB negatively regulates DNA-binding and transcriptional activities of NF-B,” Molecular and Cellular Biology, vol. 15, no. 5, pp. 2689–2696, 1995.
- J.-L. Luo, H. Kamata, and M. Karin, “IKK/NF-B signaling: balancing life and death—a new approach to cancer therapy,” Journal of Clinical Investigation, vol. 115, no. 10, pp. 2625–2632, 2005.
- P. Viatour, M.-P. Merville, V. Bours, and A. Chariot, “Phosphorylation of NF-B and IB proteins: implications in cancer and inflammation,” Trends in Biochemical Sciences, vol. 30, no. 1, pp. 43–52, 2005.
- F. Mercurio, H. Zhu, B. W. Murray et al., “IKK-1 and IKK-2: cytokine-activated IB kinases essential for NF-B activation,” Science, vol. 278, no. 5339, pp. 860–866, 1997.
- J. D. Woronicz, X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel, “IB kinase-: NF-B activation and complex formation with IB kinase- and NIK,” Science, vol. 278, no. 5339, pp. 866–869, 1997.
- E. Zandi, D. M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin, “The IB kinase complex (IKK) contains two kinase subunits, IKK and IKK, necessary for IB phosphorylation and NF-B activation,” Cell, vol. 91, no. 2, pp. 243–252, 1997.
- D. M. Rothwarf, E. Zandi, G. Natoli, and M. Karin, “IKK- is an essential regulatory subunit of the IB kinase complex,” Nature, vol. 395, no. 6699, pp. 297–300, 1998.
- S. Yamaoka, G. Courtois, C. Bessia et al., “Complementation cloning of NEMO, a component of the IB kinase complex essential for NF-B activation,” Cell, vol. 93, no. 7, pp. 1231–1240, 1998.
- F. Mercurio, B. W. Murray, A. Shevchenko et al., “IB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex,” Molecular and Cellular Biology, vol. 19, no. 2, pp. 1526–1538, 1999.
- K. H. Mellits, R. T. Hay, and S. Goodbourn, “Proteolytic degradation of MAD3 (IB) and enhanced processing of the NF-B precursor p105 are obligatory steps in the activation of NF-B,” Nucleic Acids Research, vol. 21, no. 22, pp. 5059–5066, 1993.
- C. F. Barroga, J. K. Stevenson, E. M. Schwarz, and I. M. Verma, “Constitutive phosphorylation of IB by casein kinase II,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7637–7641, 1995.
- R. Weil, C. Laurent-Winter, and A. Israel, “Regulation of IB degradation: similarities to and differences from IB,” Journal of Biological Chemistry, vol. 272, no. 15, pp. 9942–9949, 1997.
- D. Krappmann, F. G. Wulczyn, and C. Scheidereit, “Different mechanisms control signal-induced degradation and basal turnover of the NF-B inhibitor IB in vivo,” EMBO Journal, vol. 15, no. 23, pp. 6716–6726, 1996.
- S. Miyamoto, B. J. Seufzer, and S. D. Shumway, “Novel IB proteolytic pathway in WEHI231 immature B cells,” Molecular and Cellular Biology, vol. 18, no. 1, pp. 19–29, 1998.
- R. J. Phillips and S. Ghosh, “Regulation of IB in WEHI 231 mature B cells,” Molecular and Cellular Biology, vol. 17, no. 8, pp. 4390–4396, 1997.
- S. D. Shumway and S. Miyamoto, “A mechanistic insight into a proteasome-independent constitutive inhibitor B (IB) degradation and nuclear factor B (NF-B) activation pathway in WEHI-231 B-cells,” Biochemical Journal, vol. 380, no. 1, pp. 173–180, 2004.
- S. D. Shumway, M. Maki, and S. Miyamoto, “The PEST domain of IB is necessary and sufficient for in vitro degradation by -calpain,” Journal of Biological Chemistry, vol. 274, no. 43, pp. 30874–39881, 1999.
- S. D. Shumway, C. M. Berchtold, M. N. Gould, and S. Miyamoto, “Evidence for unique calmodulin-dependent nuclear factor-B regulation in WEHI-231 B cells,” Molecular Pharmacology, vol. 61, no. 1, pp. 177–185, 2002.
- Y. Jiang, J. D. Woronicz, W. Liu, and D. V. Goeddel, “Prevention of constitutive TNF receptor 1 signaling by silencer of death domains,” Science, vol. 283, no. 5401, pp. 543–546, 1999.
- J. Ninomiya-Tsuji, K. Kishimoto, A. Hiyama, J.-I. Inoue, Z. Cao, and K. Matsumoto, “The kinase TAK1 can activate the NIK-IB as well as the MAP kinase cascade in the IL-1 signalling pathway,” Nature, vol. 398, no. 6724, pp. 252–256, 1999.
- O. Takeuchi and S. Akira, “Toll-like receptors; their physiological role and signal transduction system,” International Immunopharmacology, vol. 1, no. 4, pp. 625–635, 2001.
- S. Nemoto, J. A. DiDonato, and A. Lin, “Coordinate regulation of IB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-B-inducing kinase,” Molecular and Cellular Biology, vol. 18, no. 12, pp. 7336–7343, 1998.
- J. L. Ducut Sigala, V. Bottero, D. B. Young, A. Shevchenko, F. Mercurio, and I. M. Verma, “Activation of transcription factor NF-B requiries ELKS, an IB kinase regulatory subunit,” Science, vol. 304, no. 5679, pp. 1963–1967, 2004.
- C. H. Regnier, H. Y. Song, X. Gao, D. V. Goeddel, Z. Cao, and M. Rothe, “Identification and characterization of an IB kinase,” Cell, vol. 90, no. 2, pp. 373–383, 1997.
- J. A. DiDonato, M. Hayakawa, D. M. Rothwarf, E. Zandi, and M. Karin, “A cytokine-responsive IB kinase that activates the transcription factor NF-B,” Nature, vol. 388, no. 6642, pp. 548–554, 1997.
- E. Zandi and M. Karin, “Bridging the gap: composition, regulation, and physiological function of the IB kinase complex,” Molecular and Cellular Biology, vol. 19, no. 7, pp. 4547–4551, 1999.
- H. Nakano, M. Shindo, S. Sakon et al., “Differential regulation of IB kinase and by two upstream kinases, NF-B-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3537–3542, 1998.
- C. Wu and S. Ghosh, “Differential phosphorylation of the signal-responsive domain of IB and IB by IB kinases,” Journal of Biological Chemistry, vol. 278, no. 34, pp. 31980–31987, 2003.
- E. Zandi, Y. Chen, and M. Karin, “Direct phosphorylation of IB by IKK and IKK: discrimination between free and NF-B-bound substrate,” Science, vol. 281, no. 5381, pp. 1360–1363, 1998.
- L. Ling, Z. Cao, and D. V. Goeddel, “Nf-B-inducing kinase activates IKK- by phosphorylation of Ser-176,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3792–3797, 1998.
- M. Delhase, M. Hayakawa, Y. Chen, and M. Karin, “Positive and negative regulation of IB kinase activity through IKK subunit phosphorylation,” Science, vol. 284, no. 5412, pp. 309–313, 1999.
- Y. Hu, V. Baud, M. Delhase et al., “Abnormal morphogenesis but intact IKK activation in mice lacking the IKK subunit of IB kinase,” Science, vol. 284, no. 5412, pp. 316–320, 1999.
- Z.-W. Li, W. Chu, Y. Hu et al., “The IKK subunit of IB kinase (IKK) is essential for nuclear factor B activation and prevention of apoptosis,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1839–1845, 1999.
- T. S. Doi, M. W. Marino, T. Takahashi et al., “Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 2994–2999, 1999.
- A. A. Beg and D. Baltimore, “An essential role for NF-B in preventing TNF--induced cell death,” Science, vol. 274, no. 5288, pp. 782–784, 1996.
- J. A. DiDonato, F. Mercurio, and M. Karin, “Phosphorylation of IB precedes but is not sufficient for its dissociation from NF-B,” Molecular and Cellular Biology, vol. 15, no. 3, pp. 1302–1311, 1995.
- E. B.-M. Traenckner and P. A. Baeuerle, “Appearance of apparently ubiquitin-conjugated IB- during its phosphorylation-induced degradation in intact cells,” Journal of Cell Science, vol. 19, pp. 79–84, 1995.
- Z. Chen, J. Hagler, V. J. Palombella et al., “Signal-induced site-specific phosphorylation targets IB to the ubiquitin-proteasome pathway,” Genes & Development, vol. 9, no. 13, pp. 1586–1597, 1995.
- I. Alkalay, A. Yaron, A. Hatzubai, A. Orian, A. Ciechanover, and Y. Ben-Neriah, “Stimulation-dependent IB phosphorylation marks the NF-b inhibitor for degradation via the ubiquitin-proteasome pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 23, pp. 10599–10603, 1995.
- C.-C. H. Li, R.-M. Dai, and D. L. Longo, “Inactivation of NF-B inhibitor IB: ubiquitin-dependent proteolysis and its degradation product,” Biochemical and Biophysical Research Communications, vol. 215, no. 1, pp. 292–301, 1995.
- A. Ciechanover, “The ubiquitin-proteasome proteolytic pathway,” Cell, vol. 79, no. 1, pp. 13–21, 1994.
- M. Hochstrasser, “Ubiquitin, proteasomes, and the regulation of intracellular protein degradation,” Current Opinion in Cell Biology, vol. 7, no. 2, pp. 215–223, 1995.
- A. Murray, “Cyclin ubiquitination: the destructive end of mitosis,” Cell, vol. 81, no. 2, pp. 149–152, 1995.
- K. D. Wilkinson, “Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment,” Journal of Nutrition, vol. 129, no. 11, pp. 1933–1936, 1999.
- T. Henkel, T. Machleidt, I. Alkalay, M. Kronke, Y. Ben-Neriah, and P. A. Baeuerle, “Rapid proteolysis of IB- is necessary for activation of transcription factor NF-B,” Nature, vol. 365, no. 6442, pp. 182–185, 1993.
- S.-C. Sun, J. Elwood, C. Beraud, and W. C. Greene, “Human T-cell leukemia virus type I Tax activation of NF-B/Rel involves phosphorylation and degradation of IB and RelA (p65)-mediated induction of the c-rel gene,” Molecular and Cellular Biology, vol. 14, no. 11, pp. 7377–7384, 1994.
- E. B.-M. Traenckner, S. Wilk, and P. A. Baeuerle, “A proteasome inhibitor prevents activation of NF-B and stabilizes a newly phosphorylated form of IB- that is still bound to NF-B,” EMBO Journal, vol. 13, no. 22, pp. 5433–5441, 1994.
- T. S. Finco, A. A. Beg, and A. S. Baldwin Jr., “Inducible phosphorylation of IB is not sufficient for its dissociation from NF-B and is inhibited by protease inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 25, pp. 11884–11888, 1994.
- S. Miyamoto, M. Maki, M. J. Schmitt, M. Hatanaka, and I. M. Verma, “Tumor necrosis factor -induced phosphorylation of IB is a signal for its degradation but not dissociation from NF-B,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12740–12744, 1994.
- Y.-C. Lin, K. Brown, and U. Siebenlist, “Activation of NF-B requires proteolysis of the inhibitor IB-: signal-induced phosphorylation of IB- alone does not release active NF- B,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 2, pp. 552–556, 1995.
- I. Alkalay, A. Yaron, A. Hatzubai et al., “In vivo stimulation of IB phosphorylation is not sufficient to activate NF-B,” Molecular and Cellular Biology, vol. 15, no. 3, pp. 1294–1301, 1995.
- R. Hartmann-Petersen and C. Gordon, “Proteins interacting with the 26S proteasome,” Cellular and Molecular Life Sciences, vol. 61, no. 13, pp. 1589–1595, 2004.
- V. J. Palombella, O. J. Rando, A. L. Goldberg, and T. Maniatis, “The ubiquitin-proteasome pathway is required for processing the NF-B1 precursor protein and the activation of NF-B,” Cell, vol. 78, no. 5, pp. 773–785, 1994.
- M. S. Rodriguez, J. Wright, J. Thompson et al., “Identification of lysine residues required for signal-induced ubiquitination and degradation of IB- in vivo,” Oncogene, vol. 12, no. 11, pp. 2425–2435, 1996.
- J. M. Griscavage, S. Wilk, and L. J. Ignarro, “Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-B,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 8, pp. 3308–3312, 1996.
- D. C. Scherer, J. A. Brockman, Z. Chen, T. Maniatis, and D. W. Ballard, “Signal-induced degradation of IB requires site-specific ubiquitination,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 24, pp. 11259–11263, 1995.
- L. Baldi, K. Brown, G. Franzoso, and U. Siebenlist, “Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IB-,” Journal of Biological Chemistry, vol. 271, no. 1, pp. 376–379, 1996.
- M. S. Rodriguez, I. Michalopoulos, F. Arenzana-Seisdedos, and R. T. Hay, “Inducible degradation of IB in vitro and in vivo requires the acidic C-terminal domain of the protein,” Molecular and Cellular Biology, vol. 15, no. 5, pp. 2413–2419, 1995.
- T. Aoki, Y. Sano, T. Yamamoto, and J.-I. Inoue, “The ankyrin repeats but not the PEST-like sequences are required for signal-dependent degradation of IB,” Oncogene, vol. 12, no. 5, pp. 1159–1164, 1996.
- S.-C. Sun, J. Elwood, and W. C. Greene, “Both amino- and carboxyl-terminal sequences within IB regulate its inducible degradation,” Molecular and Cellular Biology, vol. 16, no. 3, pp. 1058–1065, 1996.
- J. DiDonato, F. Mercurio, C. Rosette et al., “Mapping of the inducible IB phosphorylation sites that signal its ubiquitination and degradation,” Molecular and Cellular Biology, vol. 16, no. 4, pp. 1295–1304, 1996.
- E. W. Harhaj, S. B. Maggirwar, L. Good, and S.-C. Sun, “CD28 mediates a potent costimulatory signal for rapid degradation of IB which is associated with accelerated activation of various NF-B/Rel heterodimers,” Molecular and Cellular Biology, vol. 16, no. 12, pp. 6736–6743, 1996.
- T. A. McKinsey, J. A. Brockman, D. C. Scherer, S. W. Al-Murrani, P. L. Green, and D. W. Ballard, “Inactivation of IB by the tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-B,” Molecular and Cellular Biology, vol. 16, no. 5, pp. 2083–2090, 1996.
- R. J. Dohmen, “SUMO protein modification,” Biochimica et Biophysica Acta, vol. 1695, no. 1–3, pp. 113–131, 2004.
- R. T. Hay, “SUMO: a history of modification,” Molecular Cell, vol. 18, no. 1, pp. 1–12, 2005.
- A. M. Mabb and S. Miyamoto, “SUMO and NF-B ties,” Cellular and Molecular Life Sciences, vol. 64, no. 15, pp. 1979–1996, 2007.
- B. Liu and K. Shuai, “Regulation of the sumoylation system in gene expression,” Current Opinion in Cell Biology, vol. 20, no. 3, pp. 288–293, 2008.
- J. M. P. Desterro, M. S. Rodriguez, and R. T. Hay, “SUMO-1 modification of IB inhibits NF-B activation,” Molecular Cell, vol. 2, no. 2, pp. 233–239, 1998.
- M. S. Rodriguez, C. Dargemont, and R. T. Hay, “SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting,” Journal of Biological Chemistry, vol. 276, no. 16, pp. 12654–12659, 2001.
- D. Guo, M. Li, Y. Zhang et al., “A functional variant of SUMO4, a new IB modifier, is associated with type diabetes,” Nature Genetics, vol. 36, no. 8, pp. 837–841, 2004.
- C.-Y. Wang, P. Yang, M. Li, and F. Gong, “Characterization of a negative feedback network between SUMO4 expression and NFB transcriptional activity,” Biochemical and Biophysical Research Communications, vol. 381, no. 4, pp. 477–481, 2009.
- M. J. Matunis, E. Coutavas, and G. Blobel, “A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex,” Journal of Cell Biology, vol. 135, no. 6, pp. 1457–1470, 1996.
- R. Mahajan, C. Delphin, T. Guan, L. Gerace, and F. Melchior, “A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2,” Cell, vol. 88, no. 1, pp. 97–107, 1997.
- S. Müller, M. J. Matunis, and A. Dejean, “Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus,” EMBO Journal, vol. 17, no. 1, pp. 61–70, 1998.
- J. H. Kim and S. H. Baek, “Emerging roles of desumoylating enzymes,” Biochimica et Biophysica Acta, vol. 1792, no. 3, pp. 155–162, 2009.
- K. M. Comerford, M. O. Leonard, J. Karhausen, R. Carey, S. P. Colgan, and C. T. Taylor, “Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 986–991, 2003.
- Q. Liu, J. Li, J. Khoury, S. P. Colgan, and J. C. Ibla, “Adenosine signaling mediates SUMO-1 modification of IB during hypoxia and reoxygenation,” Journal of Biological Chemistry, vol. 284, no. 20, pp. 13686–13695, 2009.
- S. Noso, H. Ikegami, T. Fujisawa et al., “Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes,” Diabetes, vol. 54, no. 12, pp. 3582–3586, 2005.
- M. Tsurumaru, E. Kawasaki, H. Ida et al., “Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3138–3143, 2006.
- C.-Y. Wang and J.-X. She, “SUMO4 and its role in type 1 diabetes pathogenesis,” Diabetes/Metabolism Research and Reviews, vol. 24, no. 2, pp. 93–102, 2008.
- C. E. Jennings, C. J. Owen, V. Wilson, and S. H. S. Pearce, “No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves' disease,” Clinical Endocrinology, vol. 62, no. 3, pp. 362–365, 2005.
- L. J. Gibbons, W. Thomson, E. Zeggini et al., “The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis,” Rheumatology, vol. 44, no. 11, pp. 1390–1393, 2005.
- J. Costas, E. Perez-Pampin, I. Ferreiros-Vidal et al., “SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis,” Journal of Rheumatology, vol. 33, no. 6, pp. 1048–1051, 2006.
- G. Orozco, E. Sánchez, M. A. González-Gay et al., “SLC22A4, RUNX1, and SUMO4 polymorphisms are not associated with rheumatoid arthritis: a case-control study in a Spanish population,” Journal of Rheumatology, vol. 33, no. 7, pp. 1235–1239, 2006.
- G. Orozco, E. Sánchez, L. M. Gómez et al., “Study of the role of functional variants of SLC22A4, RUNX1 and SUMO4 in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 791–795, 2006.
- T. T. Huang, S. M. Wuerzberger-Davis, Z.-H. Wu, and S. Miyamoto, “Sequential modification of NEMO/IKK by SUMO-1 and ubiquitin mediates NF-B activation by genotoxic stress,” Cell, vol. 115, no. 5, pp. 565–576, 2003.
- S. M. Wuerzberger-Davis, Y. Nakamura, B. J. Seufzer, and S. Miyamoto, “NF-B activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage,” Oncogene, vol. 26, no. 5, pp. 641–651, 2007.
- A. M. Mabb, S. M. Wuerzberger-Davis, and S. Miyamoto, “PIASy mediates NEMO sumoylation and NF-B activation in response to genotoxic stress,” Nature Cell Biology, vol. 8, no. 9, pp. 986–993, 2006.
- N. D. Perkins, “Post-translational modifications regulating the activity and function of the nuclear factor B pathway,” Oncogene, vol. 25, no. 51, pp. 6717–6730, 2006.
- M. Neumann and M. Naumann, “Beyond IBs: alternative regulation of NF-B activity,” FASEB Journal, vol. 21, no. 11, pp. 2642–2654, 2007.
- R. Marienfeld, F. Berberich-Siebelt, I. Berberich, A. Denk, E. Serfling, and M. Neumann, “Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-B control,” Oncogene, vol. 20, no. 56, pp. 8142–8147, 2001.
- H. J. Maier, R. Marienfeld, T. Wirth, and B. Baumann, “Critical role of RelB serine 368 for dimerization and p100 stabilization,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 39242–39250, 2003.
- B. J. Druker, M. Neumann, K. Okuda, B. R. Franza Jr., and J. D. Griffin, “rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils,” Journal of Biological Chemistry, vol. 269, no. 7, pp. 5387–5390, 1994.
- C. Fognani, R. Rondi, A. Romano, and F. Blasi, “cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain,” Oncogene, vol. 19, no. 18, pp. 2224–2232, 2000.
- A. G. Martin and M. Fresno, “Tumor necrosis factor- activation of NF-B requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel,” Journal of Biological Chemistry, vol. 275, no. 32, pp. 24383–24391, 2000.
- S.-H. Yu, W.-C. Chiang, H.-M. Shih, and K.-J. Wu, “Stimulation of c-Rel transcriptional activity by PKA catalytic subunit ,” The Journal of Molecular Medicine, vol. 82, no. 9, pp. 621–628, 2004.
- J. Harris, S. Olière, S. Sharma et al., “Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKKε,” The Journal of Immunology, vol. 177, no. 4, pp. 2527–2535, 2006.
- C. Sánchez-Valdepeñas, A. G. Martín, P. Ramakrishnan, D. Wallach, and M. Fresno, “NF-B-inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity,” The Journal of Immunology, vol. 176, no. 8, pp. 4666–4674, 2006.
- H. Guan, S. Hou, and R. P. Ricciardi, “DNA binding of repressor nuclear factor-B p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit,” Journal of Biological Chemistry, vol. 280, no. 11, pp. 9957–9962, 2005.
- A. Ray and K. E. Prefontaine, “Physical association and functional antagonism between the p65 subunit of transcription factor NF-B and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 2, pp. 752–756, 1994.
- E. Caldenhoven, J. Liden, S. Wissink et al., “Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids,” Molecular Endocrinology, vol. 9, no. 4, pp. 401–412, 1995.
- R. I. Scheinman, A. Gualberto, C. M. Jewell, J. A. Cidlowski, and A. S. Baldwin Jr., “Characterization of mechanisms involved in transrepression of NF-B by activated glucocorticoid receptors,” Molecular and Cellular Biology, vol. 15, no. 2, pp. 943–953, 1995.
- J. Liden, I. Rafter, M. Truss, J.-A. Gustafsson, and S. Okret, “Glucocorticoid effects on NF-B binding in the transcription of the ICAM-1 gene,” Biochemical and Biophysical Research Communications, vol. 273, no. 3, pp. 1008–1014, 2000.
- R. M. Nissen and K. R. Yamamoto, “The glucocorticoid receptor inhibits NFB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain,” Genes & Development, vol. 14, no. 18, pp. 2314–2329, 2000.
- C. Martens, S. Bilodeau, M. Maira, Y. Gauthier, and J. Drouin, “Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor,” Molecular Endocrinology, vol. 19, no. 4, pp. 885–897, 2005.
- H. M. Reichardt, K. H. Kaestner, J. Tuckermann et al., “DNA binding of the glucocorticoid receptor is not essential for survival,” Cell, vol. 93, no. 4, pp. 531–541, 1998.
- H. M. Reichardt, J. P. Tuckermann, M. Göttlicher et al., “Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor,” EMBO Journal, vol. 20, no. 24, pp. 7168–7173, 2001.
- N. Auphan, J. A. DiDonato, C. Rosette, A. Helmberg, and M. Karin, “Immunosuppression by glucocorticoids: inhibition of NF-B activity through induction of IB synthesis,” Science, vol. 270, no. 5234, pp. 286–290, 1995.
- R. I. Scheinman, P. C. Cogswell, A. K. Lofquist, and A. S. Baldwin Jr., “Role of transcriptional activation of IB in mediation of immunosuppression by glucocorticoids,” Science, vol. 270, no. 5234, pp. 283–286, 1995.
- C. Brostjan, J. Anrather, V. Csizmadia et al., “Glucocorticoid-mediated repression of NFB activity in endothelial cells does not involve induction of IB synthesis,” Journal of Biological Chemistry, vol. 271, no. 32, pp. 19612–19616, 1996.
- S. Heck, K. Bender, M. Kullmann, M. Göttlicher, P. Herrlich, and A. C. B. Cato, “IB-independent downregulation of NF-B activity by glucocorticoid receptor,” EMBO Journal, vol. 16, no. 15, pp. 4698–4707, 1997.
- R. Newton, L. A. Hart, D. A. Stevens et al., “Effect of dexamethasone on interleukin-1-(IL-1)-induced nuclear factor-B (NF-B) and B-dependent transcription in epithelial cells,” The European Journal of Biochemistry, vol. 254, no. 1, pp. 81–89, 1998.
- S. Wissink, E. C. van Heerde, B. van der Burg, and P. T. van der Saag, “A dual mechanism mediates repression of NF-B activity by glucocorticoids,” Molecular Endocrinology, vol. 12, no. 3, pp. 355–363, 1998.
- K. de Bosscher, W. Vanden Berghe, and G. Haegeman, “The interplay between the glucocorticoid receptor and nuclear factor-B or activator protein-1: molecular mechanisms for gene repression,” Endocrine Reviews, vol. 24, no. 4, pp. 488–522, 2003.
- K. Ito, P. J. Barnes, and I. M. Adcock, “Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12,” Molecular and Cellular Biology, vol. 20, no. 18, pp. 6891–6903, 2000.
- K. Ito, S. Yamamura, S. Essilfie-Quaye et al., “Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-B suppression,” The Journal of Experimental Medicine, vol. 203, no. 1, pp. 7–13, 2006.
- M. Kagoshima, T. Wilcke, K. Ito et al., “Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation,” The European Journal of Pharmacology, vol. 429, no. 1–3, pp. 327–334, 2001.
- S. Saccani, S. Pantano, and G. Natoli, “p38-dependent marking of inflammatory genes for increased NF-B recruitment,” Nature Immunology, vol. 3, no. 1, pp. 69–75, 2002.
- M. Schulz, M. Eggert, A. Baniahmad, A. Dostert, T. Heinzel, and R. Renkawitz, “RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 26238–26243, 2002.
- Q. Wang, J. A. Blackford Jr., L.-N. Song, Y. Huang, S. Cho, and S. S. Simons Jr., “Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors,” Molecular Endocrinology, vol. 18, no. 6, pp. 1376–1395, 2004.
- H. Garside, A. Stevens, S. Farrow et al., “Glucocorticoid ligands specify different interactions with NF-B by allosteric effects on the glucocorticoid receptor DNA binding domain,” Journal of Biological Chemistry, vol. 279, no. 48, pp. 50050–50059, 2004.
- K. Ronacher, K. Hadley, C. Avenant et al., “Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction,” Molecular and Cellular Endocrinology, vol. 299, no. 2, pp. 219–231, 2009.
- L. Hart, L. Sam, I. Adcock, P. J. Barnes, and K. F. Chung, “Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor B in asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 1, pp. 224–231, 2000.
- O. Kassel, A. Sancono, J. Kraötzschmar, B. Kreft, M. Stassen, and A. C. B. Cato, “Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1,” EMBO Journal, vol. 20, no. 24, pp. 7108–7116, 2001.
- M. Lasa, M. Brook, J. Saklatvala, and A. R. Clark, “Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38,” Molecular and Cellular Biology, vol. 21, no. 3, pp. 771–780, 2001.
- M. Lasa, S. M. Abraham, C. Boucheron, J. Saklatvala, and A. R. Clark, “Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38,” Molecular and Cellular Biology, vol. 22, no. 22, pp. 7802–7811, 2002.
- Y. Engelbrecht, H. de Wet, K. Horsch, C. R. Langeveldt, F. S. Hough, and P. A. Hulley, “Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines,” Endocrinology, vol. 144, no. 2, pp. 412–422, 2003.
- W. Wu, S. Chaudhuri, D. R. Brickley, D. Pang, T. Karrison, and S. D. Conzen, “Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells,” Cancer Research, vol. 64, no. 5, pp. 1757–1764, 2004.
- R. Fürst, T. Schroeder, H. M. Eilken et al., “MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium,” FASEB Journal, vol. 21, no. 1, pp. 74–80, 2007.
- I. J. Cho and S. G. Kim, “A novel mitogen-activated protein kinase phosphatase-1 and glucocorticoid receptor (GR) interacting protein-1-dependent combinatorial mechanism of gene transrepression by GR,” Molecular Endocrinology, vol. 23, no. 1, pp. 86–99, 2009.
- L.-G. Bladh, K. Johansson-Haque, I. Rafter, S. Nilsson, and S. Okret, “Inhibition of extracellular signal-regulated kinase (ERK) signaling participates in repression of nuclear factor (NF)-B activity by glucocorticoids,” Biochimica et Biophysica Acta, vol. 1793, no. 3, pp. 439–446, 2009.
- E. M. King, N. S. Holden, W. Gong, C. F. Rider, and R. Newton, “Inhibition of NF-B-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occuring via p38 MAPK,” Journal of Biological Chemistry, vol. 284, no. 39, pp. 26803–26815, 2009.
- H.-S. Ro, S.-W. Kim, D. Wu, C. Webber, and T. E. Nicholson, “Gene structure and expression of the mouse adipocyte enhancer-binding protein,” Gene, vol. 280, no. 1-2, pp. 123–133, 2001.
- A. Majdalawieh, L. Zhang, I. V. Fuki, D. J. Rader, and H.-S. Ro, “Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2346–2351, 2006.
- A. Majdalawieh, L. Zhang, and H.-S. Ro, “Adipocyte enhancer-binding protein-1 promotes macrophage inflammatory responsiveness by up-regulating NF-B via IB negative regulation,” Molecular Biology of the Cell, vol. 18, no. 3, pp. 930–942, 2007.
- A. Majdalawieh and H.-S. Ro, “LPS-induced suppression of macrophage cholesterol efflux is mediated by adipocyte enhancer-binding protein 1,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 7, pp. 1518–1525, 2009.
- S. E. Reznik and L. D. Fricker, “Carboxypeptidases from A to Z: implications in embryonic development and Wnt binding,” Cellular and Molecular Life Sciences, vol. 58, no. 12-13, pp. 1790–1804, 2001.
- X. Xin, R. Day, W. Dong, Y. Lei, and L. D. Fricker, “Identification of mouse CPX-2, a novel member of the metallocarboxypeptidase gene family: cDNA cloning, mRNA distribution, and protein expression and characterization,” DNA and Cell Biology, vol. 17, no. 10, pp. 897–909, 1998.
- Y. Lei, X. Xin, D. Morgan, J. E. Pintar, and L. D. Fricker, “Identification of mouse CPX-1, a novel member of the metallocarboxypeptidase gene family with highest similarity to CPX-2,” DNA and Cell Biology, vol. 18, no. 2, pp. 175–185, 1999.
- G.-P. He, A. Muise, A. W. Li, and H.-S. Ro, “A eukaryotic transcriptional repressor with carboxypeptidase activity,” Nature, vol. 378, no. 6552, pp. 92–96, 1995.
- A. M. Muise and H.-S. Ro, “Enzymic characterization of a novel member of the regulatory B-like carboxypeptidase with transcriptional repression function: stimulation of enzymic activity by its target DNA,” Biochemical Journal, vol. 343, no. 2, pp. 341–345, 1999.
- S.-W. Kim, A. M. Muise, P. J. Lyons, and H.-S. Ro, “Regulation of adipogenesis by a transcriptional repressor that modulates MAPK activation,” Journal of Biological Chemistry, vol. 276, no. 13, pp. 10199–10206, 2001.
- P. J. Lyons, A. M. Muise, and H.-S. Ro, “MAPK modulates the DNA binding of adipocyte enhancer-binding protein 1,” Biochemistry, vol. 44, no. 3, pp. 926–931, 2005.
- L. Zhang, S. P. Reidy, T. E. Nicholson et al., “The role of AEBP1 in sex-specific diet-induced obesity,” Molecular Medicine, vol. 11, no. 1–12, pp. 39–47, 2005.
- H.-S. Ro, L. Zhang, A. Majdalawieh et al., “Adipocyte enhancer-binding protein 1 modulates adiposity and energy homeostasis,” Obesity, vol. 15, no. 2, pp. 288–302, 2007.
- S. J. Mansour, W. T. Matten, A. S. Hermann et al., “Transformation of mammalian cells by constitutively active MAP kinase kinase,” Science, vol. 265, no. 5174, pp. 966–970, 1994.
- M. G. Wilkinson and J. B. A. Millar, “Control of the eukaryotic cell cycle by MAP kinase signaling pathways,” FASEB Journal, vol. 14, no. 14, pp. 2147–2157, 2000.
- L. C. Platanias, “Map kinase signaling pathways and hematologic malignancies,” Blood, vol. 101, no. 12, pp. 4667–4679, 2003.
- P. P. Roux and J. Blenis, “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions,” Microbiology and Molecular Biology Reviews, vol. 68, no. 2, pp. 320–344, 2004.
- S. D. Rosen, J. A. Kafka, D. L. Simpson, and S. H. Barondes, “Developmentally regulated, carbohydrate binding protein in Dictyostelium discoideum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 70, no. 9, pp. 2554–2557, 1973.
- W. R. Springer, D. N. W. Cooper, and S. H. Barondes, “Discoidin I is implicated in cell-substratum attachment and ordered cell migration of Dictyostelium discoideum and resembles fibronectin,” Cell, vol. 39, no. 3, pp. 557–564, 1984.
- J. D. Johnson, J. C. Edman, and W. J. Rutter, “A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 12, pp. 5677–5681, 1993.
- S. Prag, G. D. M. Collett, and J. C. Adams, “Molecular analysis of muskelin identifies a conserved discoidin-like domain that contributes to protein self-association,” Biochemical Journal, vol. 381, no. 2, pp. 547–559, 2004.
- P. Delerive, P. Gervois, J.-C. Fruchart, and B. Staels, “Induction of IB expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor- activators,” Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703–36707, 2000.
- M. Azuma, K. Motegi, K. Aota, T. Yamashita, H. Yoshida, and M. Sato, “TGF-β1 inhibits NF-B activity through induction of IB- expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-β1,” Experimental Cell Research, vol. 250, no. 1, pp. 213–222, 1999.
- B. Saile, N. Matthes, H. El Armouche, K. Neubauer, and G. Ramadori, “The bcl, NF-B and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGFb or TNF on activated hepatic stellate cells,” The European Journal of Cell Biology, vol. 80, no. 8, pp. 554–561, 2001.
- J.-G. Park, A. Muise, G.-P. He, S.-W. Kim, and H.-S. Ro, “Transcriptional regulation by the 5 subunit of a heterotrimeric G protein during adipogenesis,” EMBO Journal, vol. 18, no. 14, pp. 4004–4012, 1999.
- W. H. Kane and E. W. Davie, “Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 18, pp. 6800–6804, 1986.
- J. D. Stubbs, C. Lekutis, K. L. Singer et al., “cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 21, pp. 8417–8421, 1990.
- C. Vijayasarathy, Y. Takada, Y. Zeng, R. A. Bush, and P. A. Sieving, “Retinoschisin is a peripheral membrane protein with affinity for anionic phospholipids and affected by divalent cations,” Investigative Ophthalmology and Visual Science, vol. 48, no. 3, pp. 991–1000, 2007.
- A. Arakawa, M. Matsuo-Takasaki, A. Takai et al., “The secreted EGF-Discoidin factor xDel1 is essential for dorsal development of the Xenopus embryo,” Developmental Biology, vol. 306, no. 1, pp. 160–169, 2007.
- S. Baumgartner, K. Hofmann, R. Chiquet-Ehrismann, and P. Bucher, “The discoidin domain family revisited: new members from prokaryotes and a homology-based fold prediction,” Protein Science, vol. 7, no. 7, pp. 1626–1631, 1998.
- R. Sen and D. Baltimore, “Multiple nuclear factors interact with the immunoglobulin enhancer sequences,” Cell, vol. 46, no. 5, pp. 705–716, 1986.
- J. E. Thompson, R. J. Phillips, H. Erdjument-Bromage, P. Tempst, and S. Ghosh, “IB- regulates the persistent response in a biphasic activation of NF-B,” Cell, vol. 80, no. 4, pp. 573–582, 1995.
- J.-I. Inoue, L. D. Kerr, A. Kakizuka, and I. M. Verma, “IB, a 70 kd protein identical to the C-terminal half of p110 NF-B: a new member of the IB family,” Cell, vol. 68, no. 6, pp. 1109–1120, 1992.
- S. T. Whiteside, J.-C. Epinat, N. R. Rice, and A. Israeöl, “, a novel member of the IB family, controls RelA and cRel NF-B activity,” EMBO Journal, vol. 16, no. 6, pp. 1413–1426, 1997.
- G. P. Nolan, T. Fujita, K. Bhatia et al., “The bcl-3 proto-oncogene encodes a nuclear IB-like molecule that preferentially interacts with NF-B p50 and p52 in a phosphorylation- dependent manner,” Molecular and Cellular Biology, vol. 13, no. 6, pp. 3557–3566, 1993.
- F. Mercurio, J. A. DiDonato, C. Rosette, and M. Karin, “p105 and p98 precursor proteins play an active role in NF-B-mediated signal transduction,” Genes & Development, vol. 7, no. 4, pp. 705–718, 1993.
- T. Fujita, G. P. Nolan, S. Ghosh, and D. Baltimore, “Independent modes of transcriptional activation by the p50 and p65 subunits of NF-B,” Genes & Development, vol. 6, no. 5, pp. 775–787, 1992.
- R. Lin, D. Gewert, and J. Hiscott, “Differential transcriptional activation in vitro by NF-B/Rel proteins,” Journal of Biological Chemistry, vol. 270, no. 7, pp. 3123–3131, 1995.
- J. L. Pomerantz, E. M. Denny, and D. Baltimore, “CARD11 mediates factor-specific activation of NF-B by the T cell receptor complex,” EMBO Journal, vol. 21, no. 19, pp. 5184–5194, 2002.
- G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors and induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.
- M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
- Y.-C. Zhou and D. J. Waxman, “Cross-talk between Janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor- (PPAR) signaling pathways: growth hormone inhibition of PPAR transcriptional activity mediated by STAT5b,” Journal of Biological Chemistry, vol. 274, no. 5, pp. 2672–2681, 1999.
- D. S. Straus, G. Pascual, M. Li et al., “15-deoxy--prostaglandin inhibits multiple steps in the NF-B signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4844–4849, 2000.
- S. B. Joseph, A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz, “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors,” Nature Medicine, vol. 9, no. 2, pp. 213–219, 2003.
- A. Castrillo, S. B. Joseph, C. Marathe, D. J. Mangelsdorf, and P. Tontonoz, “Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages,” Journal of Biological Chemistry, vol. 278, no. 12, pp. 10443–10449, 2003.
- J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003.
- L. Chang, Z. Zhang, W. Li, J. Dai, Y. Guan, and X. Wang, “Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-B pathway,” Biochemical and Biophysical Research Communications, vol. 357, no. 3, pp. 772–778, 2007.
- T. L. Bonfield, M. J. Thomassen, C. F. Farver et al., “Peroxisome proliferator-activated receptor- regulates the expression of alveolar macrophage macrophage colony-stimulating factor,” The Journal of Immunology, vol. 181, no. 1, pp. 235–242, 2008.
- S. J. Park, K. S. Lee, S. R. Kim et al., “Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation,” The Journal of Immunology, vol. 183, no. 5, pp. 3259–3267, 2009.
- S. W. Chung, B. Y. Kang, S. H. Kim et al., “Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor- and nuclear factor-B,” Journal of Biological Chemistry, vol. 275, no. 42, pp. 32681–32687, 2000.
- R. Weil, H. Sirma, C. Giannini et al., “Direct association and nuclear import of the hepatitis B virus X protein with the NF-B inhibitor IB,” Molecular and Cellular Biology, vol. 19, no. 9, pp. 6345–6354, 1999.
- H. Gao, Y. Sun, Y. Wu et al., “Identification of -arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-B pathways,” Molecular Cell, vol. 14, no. 3, pp. 303–317, 2004.
- D.-K. Lee, J.-E. Kang, H.-J. Park et al., “FBI-1 enhances transcription of the nuclear factor-B (NF-B)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-B,” Journal of Biological Chemistry, vol. 280, no. 30, pp. 27783–27791, 2005.
- G. Le Negrate, A. Krieg, B. Faustin et al., “ChlaDub1 of Chlamydia trachomatis suppresses NF-B activation and inhibits IB ubiquitination and degradation,” Cellular Microbiology, vol. 10, no. 9, pp. 1879–1892, 2008.
- D. Sorriento, M. Ciccarelli, G. Santulli et al., “The G-protein-coupled receptor kinase 5 inhibits NFB transcriptional activity by inducing nuclear accumulation of IB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 46, pp. 17818–17823, 2008.
- V. Doceul, B. Charleston, H. Crooke, E. Reid, P. P. Powell, and J. Seago, “The Npro product of classical swine fever virus interacts with IB, the NF-B inhibitor,” The Journal of General Virology, vol. 89, no. 8, pp. 1881–1889, 2008.
- E. B. Kopp and R. Medzhitov, “The Toll-receptor family and control of innate immunity,” Current Opinion in Immunology, vol. 11, no. 1, pp. 13–18, 1999.
- G. Zhang and S. Ghosh, “Molecular mechanisms of NF-B activation induced by bacterial lipopolysaccharide through Toll-like receptors,” The Journal of Endotoxin Research, vol. 6, no. 6, pp. 453–457, 2000.
Copyright © 2010 Amin Majdalawieh and Hyo-Sung Ro. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.